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The Role of ROS in the Progression and Treatment of Castration-Resistant Prostate
Cancer
Dannah Miller
University of Nebraska Medical Center, 2019

Supervisor: Ming-Fong Lin, Pharm.D., Ph.D.

Prostate cancer is the second leading cause of cancer-related deaths in U.S. men, primarily due to
the development of castration-resistant (CR) prostate cancer (PCa), of which there are no effective
treatment options. Reactive oxygen species (ROS) plays a critical role in prostate carcinogenesis,
including the progression of the CR PCa phenotype. ROS regulates both cell proliferation and
apoptosis; a moderate increase in ROS can promote proliferation; however, a substantial rise in
ROS levels will result in apoptosis. Oxidase p66Shc is elevated in clinical PCa cells and has been
associated with a metastatic phenotype of CR PCa cells, promoting PCa cell proliferation and
migration in culture. However, ROS generated by p66Shc can also result in apoptosis. Our working
hypothesis is that aberrant p66Shc/ROS production promotes PCa progression to the CR
phenotype.
Within our studies, we have demonstrated that hydrogen peroxide treatment can promote an
aggressive, AI phenotype in androgen-sensitive (AS) PCa cells. Furthermore, we attribute these
ROS-mediated phenotypic and cell signaling alterations to p66Shc. In our second study, we can
effectively mitigate CR PCa, neuroendocrine-like PCa and docetaxel-resistant PCa growth by
exploiting this ROS balance and promoting excessive ROS production via treatments with
microtubule targeting agents CIL-102 derivatives. These selective anti-cancer agents are promising
new therapeutic options for not only PCa, but other taxane-resistant cancers via depolymerization
of microtubules.
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Chapter 1

Introduction

2
1. Prostate Cancer Progression to the Castration-Resistant Phenotype
Prostate cancer (PCa) is the most commonly diagnosed solid tumor and predicted to be the
second leading cause of cancer-related death of U.S. men in 2019 [1-4]. Typically,
localized PCa is not lethal and can be effectively treated by surgery or radiation. In some
instances, PCa patients may not require treatment if the tumor is less aggressive, in which
a “watchful waiting” method is utilized to monitor the tumor [5,6]. In most cases, PCa is
not life-threatening until the tumor invades surrounding tissue and/or becomes metastatic.
Thus, the ability to distinguish lethal tumors from those that are less aggressive is the
subject of intense focus in the field of PCa research.
Prostate epithelial cells express androgen receptor (AR), thus PCa growth and survival are
regulated by androgens. Therefore, metastatic PCa is initially treated with androgen
deprivation therapy (ADT) via surgical or chemical castration [7-9]. However, many PCa
patients relapse into the castration-resistant (CR) form of the disease three to five years
after the initiation of ADT (Fig. 1.1) [10]. Despite the lack of response to ADT, most CR
PCa still maintains reliance on AR signaling and androgens for receptor activation [11].
Androgen-independence, or the CR phenotype, can result from AR overexpression,
alteration in AR structure or function, intratumoral androgenic steroid synthesis, and/or
ligand-independent AR activation by growth factor pathways such as ErbB2 [12-15]. AR
can also be activated by non-androgens such as estrogen or hydrocortisone or by low levels
of circulating androgens due to mutations that increase receptor promiscuity [16]. Enzymes
involved in androgen biosynthesis are often overexpressed leading to enhanced levels of
intratumoral androgens for intracrine activation of AR [14,17,18]. Current therapeutic
strategies for CR PCa include the antiandrogens enzalutamide, abiraterone acetate, and
bicalutamide as well as the chemotherapeutic agent, docetaxel, to slow the disease’s
progression [19,20]. However, the most effective therapies for CR PCa can only extend
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patient survival by several months; therefore, there is an immediate need for more effective
treatment options [20]. Various molecules involved in the process of CR PCa cell
proliferation, survival, and migration have the potential to be promising new targets for
metastatic PCa. Understanding the regulation of CR PCa progression would allow for the
development of new therapies and advancements to reduce deaths due to this lethal disease.

2. Reactive Oxygen Species
A. Cellular ROS Balance
i. Sources of ROS
Reactive oxygen species (ROS) are radicals, ions, or molecules that have a single unpaired
electron in the outermost electron shell; therefore, these molecules are highly reactive. ROS
is often generated as by-products of cellular metabolism primarily due to cellular
respiration in the mitochondria [21,22]. Due to superoxide dismutase 2 (SOD2) localization
within the mitochondria, the superoxide produced from the electron transport chain (ETC)
is converted to hydrogen peroxide, which is then converted into water via catalase. This
antioxidant system keeps ROS to prevent cellular oxidative damage.
Within the cell, there are a variety of proteins that generate ROS, termed oxidases. These
ROS-producing proteins can be localized to a variety of locations within the cell, including
the ER, peroxisomes, cell and nuclear membranes, and the cytoplasm. A prominent
example is NADPH oxidase (NOX), which can generate superoxide via reduction of
molecular oxygen using NADPH as the electron donor. Androgens have been
demonstrated to increase levels of NOX2 and NOX4 as well as superoxide in PCa, which
allows for resistance to radiation [23], while other studies have concluded that NOX2,
NOX4, and NOX5 are associated with PCa proliferation and survival [24].
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Another well-studied protein that can promote ROS generation is p66Shc, a 66 kDa protooncogene Src and collagen homolog protein that is one of three members of the Shc family,
including isoforms p52Shc and p46Shc [25,26]. While p52Shc and p46Shc are
ubiquitously expressed, p66Shc expression is more tightly regulated due to the presence of
an alternative promoter which provides p66Shc with additional cytochrome C-binding
(CB) and N-terminal collagen homology 2 (CH2) domains [25,27-30]. In the cytosol,
p66Shc can promote the formation and activity of the NOX complexes, leading to the
production of superoxide. Upon mitochondrial translocation, p66Shc binds and oxidizes
cytochrome C via its CB domain, which uncouples the electron transport chain and
promotes the generation of ROS, particularly superoxide [31].
ii. Antioxidant Pathways
Both superoxide and hydrogen peroxide are only moderately reactive to organic molecules,
partly because of their rapid elimination by antioxidant enzymes such as SODs, catalase
(CAT),

and glutathione peroxidase (GPx),

and/or

nonenzymatic

antioxidants,

including vitamin C, vitamin E, flavonoids, and glutathione (GSH) [32,33]. Unfortunately,
cells have no enzymatic mechanism for elimination of hydroxyl radical, and, thus, its
excess production can eventually lead to cell death. Fortunately, the likelihood of formation
of these toxic molecules can be reduced via increased protein levels and activity of SOD
and catalase, although there will continue to remain the potential for the reaction of
hydrogen peroxide with free iron that still generate hydroxyl radicals [32-34].
Several transcription factors respond to increased ROS levels and promote the expression
of a variety of antioxidant enzymes. Transcription factor NF-E2-related factor 2 (Nrf2) is
a notable protein that can bind to the antioxidant response element (ARE) sequence within
the promoter region of numerous genes. Nrf2 is a transcriptional activator that plays a
central role in the inducible expression of cytoprotective genes in response to oxidative
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stress [35,36]. Under non-stressed conditions, the majority of Nrf2 resides in the
cytoplasm [37] and associates with a dimeric inhibitory protein, Kelch-like ECHassociated protein-1 (Keap1). Keap1 interacts with the cullin-3 E3-ubiquitin ligase (Cul3)
and serves as a platform for the ubiquitination and resultant proteasomal degradation of
Nrf2. Increased ROS levels result in oxidation of Keap1, allowing for the translocation of
Nrf2 to the nucleus [37]. In the nucleus, Nrf2 dimerizes with members of the b-zip family,
termed the small Maf proteins. The Nrf2-small Maf heterodimer binds to the ARE enhancer
and activates ARE-dependent transcription of target genes which serve as antioxidants
involved in cellular processes such as electrophile detoxification, GSH synthesis, and ROS
homeostasis (Fig. 1.3) [35,38,39].
B. ROS in Normal Physiological Signaling
ROS play an important role in essential cell signaling pathways. ROS in low concentrations
are indispensable second messengers for transmitting signals throughout the cell [39].
Alterations in the intracellular redox state occur primarily through oxidation of protein
sulfhydryl groups and can modulate cell signaling, DNA synthesis, enzyme activation,
selective gene expression, regulation of cell cycle, and cell survival. High doses of ROS
damages cellular components directly and inactivates proteins or signaling pathways
because sulfhydryl-containing proteins are highly susceptible to oxidation. Thus, the fate
and function of a cell is determined by the level of ROS (Fig. 1.2). This is critical because
lower redox status in the cell promotes proliferation over apoptosis via changes in signaling
pathways.
i.

MAPK pathways
The mitogen-activated protein kinase (MAPK) cascades consist of four major MAPKs: the
extracellular signal-related kinases (ERK1/2), the c-Jun N-terminal kinases (JNK), the p38
kinase (p38), and the big MAP kinase 1 (BMK1/ERK5). These kinases play pivotal roles
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in cellular responses to a wide variety of signals elicited by growth factors, hormones, and
cytokines, in addition to genotoxic and oxidative stressors. MAPK pathways are composed
of a three-kinase tier: MAPK kinase kinases (MAPKKK) phosphorylate and activate
MAPK kinases (MAPKK), which phosphorylate and activate MAPKs [40]. One such
example of the MAPK cascade is apoptosis signal-regulated kinase 1 (ASK1), an upstream
MAPKKK that regulates the JNK and p38 MAPK through MKK4, MKK3, and MKK6
MAPKKs. Interestingly, thioredoxin interacts with ASK1 and directly inhibits its kinase
activity [41-43]. Upon ROS oxidation of two cysteine residues of thioredoxin, thioredoxin
dissociates from ASK1, allowing for the subsequent N-terminal homophilic interaction and
complete oligomerization and activation of ASK1 [41]. Interestingly, ROS-activated
ASK1 mediates p38 signaling leading to non-apoptotic outcomes also, such as
differentiation and immune signaling; thus, reinforcing the role of ROS signaling in
cellular homeostasis [40,44,45].
MAPK p38 is described as a stress-activated protein kinase that is primarily activated
through extracellular stresses and cytokines, such as tumor necrosis factor-α (TNF-α)
and interleukin-1β (IL-1β), and, thus, has been studied in the context of inflammation [46].
Once activated by MEK3 or MEK6, p38 can activate pathways involved in stress response
or cell migration [45, 47,48]. Interestingly, the ROS-mediated stress response by p38 can
be involved in cell survival [49], cell cycle arrest [50], and apoptosis [51-53].
The JNKs, which are also stress-activated protein kinases, are known for their ability to
phosphorylate the N-terminal transactivating domain of the transcription factor c-Jun
[53,54]. Two MEK family members, MEK4 and MEK7, have been shown to
phosphorylate JNKs [54], which results in the activation of several transcription factors
[55]. One example of ROS regulation of JNK involves TRAF4 (TNF receptor-associated
factor 4), a component of the TNFα signaling pathway. TRAF4 binds to the NOX complex
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to activate JNK [56], suggesting that death receptors may use several ways to induce ROS
within cells. In response to ROS, JNKs catalyze the phosphorylation and downregulation
of anti-apoptotic proteins such as Bcl-2 (B-cell lymphoma 2) and Bcl-XL (B-cell
lymphoma-extra large) [57], which are known to protect cells from ROS-mediated
apoptosis [58,59]. JNK also alters the Bax/Bcl-2 complex by increasing the expression of
Bax, leading to the formation of porous Bax homodimer complexes that lead to dissipation
of mitochondrial membrane integrity and cell death [60].
The ERK pathway is often activated by growth factors such as epidermal growth factor
(EGF) and platelet-derived growth factor (PDGF) [61]. Briefly, ligands bound to growth
factor receptors can promote signaling of the Raf/MEK/ERK cascade through
different isoforms of the small GTP-binding protein Ras [62]. ROS has also been shown to
activate growth factor receptors in the absence of the growth factor receptor ligands
[63]. For example, EGF receptor (EGFR) is one receptor tyrosine kinase (RTK) that is
most commonly activated through ligand-induced dimerization or oligomerization for the
regulation of cell proliferation, survival, migration, and differentiation [63]. Interestingly,
ROS can activate EGFR even in the absence of its ligand, leading to enhanced ERK
activation [64].
ii.

Phosphatases
There are ∼100 human genes in the protein tyrosine phosphatase (PTP) family, which

include the classical pTyr-specific phosphatases and dual specificity phosphatases (DSPs),
which may also dephosphorylate Ser/Thr residues, and nonprotein substrates, such
as inositol phospholipids. The PTP signature motif [I/V]HCXXGXXR[S/T] contains an
invariant Cys residue, which functions as a nucleophile in catalysis. This Cys residue has
an unusually low pKα, which enhances its nucleophilic properties, making it susceptible to
oxidation. Interestingly, PTPs are essential targets of ROS for enhanced activation of RTKs
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in response to a variety of stimuli. Oxidation of the active site Cys abrogates its
nucleophilic properties, thereby, inhibiting PTP activity [65-67]. Thus, one function of
ROS is to inactivate the PTPs that negatively regulate RTKs to maintain a constant or
enhanced signaling response.
One signaling pathway that plays a vital role in cell proliferation in response to growth
factor and hormone stimulation is the phosphoinositide 3-kinase (PI3K) pathway. PI3K is
tightly coupled with RTKs activated by various growth factors such as EGF, PDGF, nerve
growth factor (NGF), insulin, and vascular endothelial growth factor (VEGF). PI3K is
recruited to activate tyrosine-phosphorylated RTK dimers through an SH2 domain in the
PI3K p85 regulatory subunit. PI3K then catalyzes the synthesis of the second messenger
phosphatidylinositol 3,4,5 triphosphate (PIP3) from phosphatidylinositol 4,5 bisphosphate
(PIP2), wherein the membrane-bound PIP3 serves as a signaling molecule to recruit
proteins containing the pleckstrin homology (PH) domain. These PH domain proteins, such
as the phosphoinositide-dependent protein kinase (PDK) and protein kinase B (AKT)
serine/threonine kinases, are then activated and mediate further downstream signaling
events [68]. The synthesis of PIP3 is negatively regulated by phosphatase and tensin
homology (PTEN) phosphatase, which dephosphorylates PIP3 to PIP2 [69]. Through
PTEN, the PI3K pathway is subject to reversible redox regulation by ROS generated by
growth factor stimulation. Hydrogen peroxide oxidizes and inactivates human PTEN
through disulfide bond formation between the catalytic domain Cys-124 and Cys-71
residues [69,70]. PTEN oxidation is reversible by peroxiredoxin II, a cytoplasmic
peroxiredoxin isoform that eliminates hydrogen peroxide generated in response to growth
factors [70]. Thus, the PI3K pathway is regulated by protein phosphatases that are directly
oxidized via ROS resulting in sustained activation of the signaling pathways.
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In PCa, cellular prostatic acid phosphatase (cPAcP) removes a phosphate group from ErbB2 resulting in an inactive RTK that cannot carry out its function of promoting cell
tumorigenicity. PAcP is a dual specificity prostate-specific phosphatase that can
dephosphorylate Tyr, Ser, and Thr residues with a preference for p-Tyr [71-73]. To
enhance ErbB-2 signaling, ROS is produced in the ETC and inhibits PAcP [66,67].
Similarly, treatment of LNCaP cells with hydrogen peroxide was shown to increase pTyr1221/1222 levels of ErbB-2 and cell proliferation; while antioxidant N-acetyl cysteine
can block hydrogen peroxide-induced ErbB-2 phosphorylation [66,67]. It was further
determined that p66Shc/ROS-mediated inactivation of cPAcP phosphatase activity is the
mechanism through which ErbB-2 activation is achieved in PCa [66,67]. In summary,
androgen up-regulation of p66Shc protein levels results in increased cellular levels of ROS,
which oxidize and inactivate cPAcP; thus, preventing PAcP from dephosphorylating ErbB2 and leading to elevated ErbB-2 activation thus promoting the CR PCa phenotype.
Figure 1.4 shows several different sources of ROS production and also demonstrates the
ROS-mediated regulation of numerous protiens and their effects on the cell. Oxidases
xanthine oxidase, and NOX enzymes, as well as the ETC are notable sources of superoxide
production. Superoxide is often converted to H2O2, a less toxic species via superoxide
dismutases or into nontoxic water via catalase, glutathione peroxidase, or peroxiredoxin.
Although less reactive, H2O2 can readily oxidize critical redox-sensitive Cys in signaling
proteins, including those we have discussed above: PTPs, protein tyrosine kinases (PTKs),
protein kinase C (PKC), MAPKs, and transcriptional factors.

3. Reactive Oxygen Species and Prostate Cancer
Cancer cells often have an abundant generation of ROS from increased activity of
mitochondria as well as by the activation of oxidase enzymes [74]. The high rate of ROS
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production is counterbalanced by antioxidant activity in order to maintain redox balance
[75]. If cancer cells do not control their ROS levels, then they are susceptible to oxidativestress-induced cell death [76,77]. Thus, cancer cells have developed mechanisms to survive
toxic ROS levels and promote a tumorigenic phenotype.
A. Oxidation of DNA, Protein, and Lipids
When cellular production of ROS overpowers its antioxidant capacity, damage to
organisms and cellular macromolecules such as lipids, proteins, and nucleotides as well as
apoptosis may ensue [21]. Furthermore, damaged macromolecules can have adverse
outcomes for the cell, including the development and progression of cancer or cell death.
Oxygen radicals produce more than 30 different DNA adducts which can be mutagenic and
contribute to the etiology of cancer. Some ROS such as hydrogen peroxide are less reactive
towards DNA, whereas hydroxyl radicals rapidly oxidize DNA bases as well as single
strand and double strand breaks [78,79]. Although the majority of the DNA damage is
removed by DNA repair processes, a small number of lesions escape repair and can
accumulate with age. High levels of damage to DNA can lead to cell death. Nevertheless,
the cells harboring DNA mutations that can successfully avoid cell death increase the risk
of carcinogenesis and cancer growth [22].
The primary function of lipids is to store energy for the body. Lipid oxidation products are
being intensively investigated because of their potential to cause injury and their
pathogenic role has been described in several diseases, including cancer [80]. ROS can
react with polyunsaturated or polyunsaturated fatty acids to initiate lipid peroxidation and
create peroxides and aldehydes [81,82]. Lipid oxidation generates copious amounts of toxic
molecules such as malondialdehyde, 2-alkenals, and 4-hydroxy-2-alkenals [83], which can
inflict damage throughout the cell [84]. Reactive lipids can accumulate to high levels,
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which allows for reaction of these molecules with lysine, histidine, or cysteine residues and
often results in altered protein function [85].
Cellular proteins are exposed to oxidative modification and other damage through
oxidative stress, disease, and as a consequence of aging. Some ROS-induced modifications
also increase protein carbonylation, nitration of Tyr and Phe residues, and protein
degradation [86], or the formation of cross-linked and glycated proteins [87,88], which can
alter protein function. For example, irreversible oxidation of phosphatases within the
catalytic sites hinders their enzymatic activity [89]. Oxidative alterations of enzymes also
impacts DNA repair efficiency, the fidelity of DNA polymerase during replication and
transcriptional activity, which tightly associates with cancer [90,91]. Further, the
accumulation of oxidatively damaged proteins leads to cells susceptible to cell death [92].
Numerous studies have demonstrated increased detection of nucleotide, lipid, and protein
oxidation in PCa as compared to benign tissues. Increased ROS levels can be shown
through elevated levels of oxidative damage markers malondialdehyde and 8-oxoguanine
(8-oxoG) in PCa [93,94]. Further, increased levels of lipid peroxidation, such as 4hydroneonal (4-HNE), have been detected in PCa tissue samples compared to benign
prostate epithelium [95,96]. Oberley et al. demonstrated that protein nitrosylation, which
can both activate and inhibit proteins, occurs more frequently in PCa tissues compared to
the normal prostate epithelium [96]. Protein nitrosylation was even higher in metastatic
PCa compared to primary PCa [96]. A specific example of protein oxidation in PCa
includes phosphatases such as PAcP, as discussed in Section 2.B.ii. Briefly, ROS produced
via p66Shc selectively targets PAcP, leading to enhanced activity of ErbB-2 and resulting
in pro-survival and proliferative signaling [66,67].
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B. Effects of Reactive Oxygen Species on Proliferation and Migration
Interestingly, the progression of many types of cancers is regulated by cellular ROS,
including PCa [96]. Elevated rates of ROS have been detected in almost all cancers, where
they promote many aspects of tumor development and progression [97,98]. Low doses of
hydrogen peroxide and superoxide stimulate cell proliferation in a wide variety of cancer
cell types [24,90,99]. Further, decreased SOD2 activity favors proliferation, due to
increased superoxide and low hydrogen peroxide levels, while increasing SOD2 activity
drives the proliferating cells to quiescence [100,101]. ROS can also upregulate the mRNA
levels of cyclins that participate in the cell cycle to expedite G1 to S phase transition,
including cyclin B2, cyclin D3, cyclin E1 and cyclin E2 [63,102]. Additionally, ROS has
been shown to promote PCa proliferation, migration, invasion, and metastasis [24] and
activation of AR can result in increased ROS generation due to augmented mitochondrial
activity [103].
Conversely, antioxidants inhibit tumor cell proliferation. For example, pancreatic cancer
cell lines generally show high basal levels of endogenous oxidative stress as compared to
normal cells [90]. These increased ROS levels have been linked to increased proliferation.
Moreover, the expression levels and activities of endogenous SOD1, SOD2, CAT, and GPx
inversely correlate with cell doubling times in various pancreatic cancer cell lines
[104,105]. Interestingly, these proteins have unaltered or reduced expression in PCa
compared to benign prostate epithelial tissues [95,106]. Furthermore, treatment of LNCaP
cells with antioxidant selenium resulted in cell cycle arrest via p21 upregulation [107].
Altogether, this suggests ROS as positive regulators of tumor cell proliferation by
modulating essential proteins in cell cycle progression.
Similarly, ROS can promote migration and metastasis of cancer cells as well. The treatment
of carcinoma cells with hydrogen peroxide prior to intravenous injection into mice

13
enhanced metastasis [108]. Additionally, subpopulations of low- or non-motile MCF-7
breast cancer cells that possess higher levels of endogenous ROS than the parental cells
showed increased motility. Furthermore, orthotopic tumors generated with the high
endogenous ROS MCF-7 cells metastasized to lung, liver, and spleen [109]. An increase
in ROS can also contribute to increased cytoskeleton remodeling, motility, and epithelialto-mesenchymal transition (EMT) [110-113]. Targets for ROS in these processes are SHP2, FAK (focal adhesion kinase), MW-PTP, RTKs, Src-family kinases, and PYK2 (prolinerich tyrosine kinase 2). In PCa, activation of phosphatases and Src occurs through direct
oxidation [114,115], whereas activation of FAK and PYK2 are indirect through upstream
signaling events leading to tyrosine phosphorylation [116]; thus, contributing to cell
spreading, cell migration and prevention of cell death. Furthermore, inactivation of
phosphatases including PTEN and PAcP results in increased CXCR4, AKT, and ErbB-2
activity, thus promoting PCa cell survival, proliferation, and metastasis [24,66,67,115].
This illustrates that the intracellular redox state governs crucial steps of the metastatic
process, including cell adhesion to extracellular matrix (ECM), anchorage-independent
survival, and increased migratory and invasive potential.

C. Manipulation of Reactive Oxygen Species for Prostate Cancer Treatment
Disproportional increases in cellular ROS can induce cancer cell cycle arrest, senescence,
and apoptosis. This can be achieved with cancer chemotherapy, depletion of cells from
antioxidant proteins or generation of ROS by immune cells. Radiation therapy utilizes high
energy beams to produce excessive amounts of ROS that will result in cancer cell death.
PCa patients can be treated with ADT in combination with radiation to maximize the
reduction of the cancer cells and the tumor size. One study concluded that patients who
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received radiation therapy plus ADT had significantly higher survival and lower PCa–
specific mortality compared to ADT alone [116].
Research has also shown that some antioxidants can result in apoptosis or cellular
senescence in cancer. It is hypothesized that antioxidants can be used to halt PCa tumor
progression; therefore, several clinical trials analyzed the overall risk for cancer
development when patients are given antioxidant supplements, such as Vitamin E. These
interventional and observational studies included alpha-Tocopherol, beta-carotene
prevention (ATBC), selenium and vitamin E cancer prevention trial (SELECT), and
prostate, lung, colorectal, and ovarian cancer screening trial (PLCO), among many others.
However, few studies were able to demonstrate a reduction in the risk of PCa development
with antioxidant supplements [117-120]. Nevertheless, many scientists and dieticians have
discussed the shortcomings of these studies, including a dosage of antioxidants, the use of
only one isoform, and the patient population in which these studies have been conducted
[121,122]. Thus, dietary and supplemental antioxidants may inhibit carcinogenesis;
however, compelling data also demonstrate that antioxidants can exacerbate the
progression of the cancer process.
An alternative approach to utilizing ROS scavenging molecules to influence cancer growth
is through manipulating the expression of antioxidant genes, such as SOD1/2 or Nrf2.
Several studies have demonstrated that increased expression of SOD2 lead to tumor
suppression through reduced ROS as well as increased expression of other tumor
suppressor genes [123-125]. Furthermore, all three SOD isoforms are downregulated in
PCa, suggesting their role in tumor suppression [106]. Nrf2 activation has also been
reported to be involved in suppression of PCa cell growth and migration [126]. As such,
upregulation of antioxidant genes could be an effective modality to suppress clinical PCa
growth. Manipulation of ROS molecules through SOD mimetics is another therapeutic
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option that produces similar results to upregulation of antioxidant genes. Several studies
have demonstrated the ability of these SOD mimetic molecules to not only inhibit PCa
growth via altering ROS levels [127,128], but also through suppression of p300 [129] and
AR activity [130]. Thus, contrary to utilization of antioxidants to suppress cancer growth,
antioxidant gene expression and enhanced activity of these proteins halt the progression of
the cancer process and are currently being studied for their anti-cancer properties in clinical
trials.

4. Conclusion and Transition
While androgen-sensitive (AS) PCa is effectively treated by ADT, therapeutic options for
CR PCa remain limited with no adequate treatment available. Moreover, most current
treatment strategies for CR PCa continue to focus on AR inhibition. Therefore, new
therapeutic targets must be identified, and the synthesis of novel curative agents is required.
Targeting the redox balance in PCa cells is one potential method which may be beneficial
to patients. The tightly regulated process of redox signaling can promote cancer cell growth
and migration; however, an imbalance can result in senescence or cell death. Therefore,
the following studies investigate the effects of novel ROS-generating therapeutic
compounds on PCa cell growth and survival. We also seek to further elucidate the role of
ROS in the progression of PCa to the CR phenotype role of p66Shc in regulating prostate
cancer progression in an attempt to identify additional therapeutic targets.
Figure 1.5 represents the working hypothesis for the role of ROS in PCa progression.
Suboptimal ROS levels result in cell senescence, while excessive ROS levels can result in
cell cytotoxicity and promote apoptosis. At the optimal level of ROS, cells exhibit the
highest potential of proliferation, migration, and invasion. The AS PCa cells, including
LNCaP-AS, MDA PCa2b-AS, and VCaP-AS PCa cells, can be treated with hydrogen
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peroxide or increasing levels of oxidases to promote their tumorigenic phenotypes, while
NAC or antioxidant enzymes will cause the cells to enter senescence. Conversely, AI PCa
cells have above optimal ROS levels; thus, NAC or antioxidants will enhance
tumorigenicity and hydrogen peroxide treatment results in cell death. Our studies
demonstrate that oxidase p66Shc is one source of ROS that can promote the AI phenotype
in PCa cells. Further, CIL-102 derivatives can push AI PCa cells towards apoptosis via
inhibition of microtubule polymerization and ROS production.
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Figures

Figure 1.1. Prostate Cancer Progression
Initially, localized PCa is treated with surgery and radiation therapy, which results in remission of
the tumor. There is potential for cancer to return and become metastatic, at which point physicians
will rely on ADT to reduce the tumor burden as PCa relies on this steroid hormone for survival and
growth. ADT will be effective for three to five years, and then the tumor will likely relapse. Because
the PCa can survive in an environment depleted of androgens, the cancer is now CR PCa. CR PCa
can be treated with chemotherapeutic agents such as docetaxel; however, this will only extend a
patient’s life by several months before the succumb to the disease.
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Figure 1.2. ROS Balance in Cancer
The balance of ROS in a cell can affect cell proliferation and cell death. Normal physiological
levels of ROS are relatively low; however, these molecules are essential as signaling molecules
which can alter signaling pathways via oxidation of proteins. Reduced ROS levels are cytostatic
and result in cell senescence. A moderate increase in ROS from normal physiological levels can
promote tumorigenicity via oxidation of tumor suppressors and activation of proliferative signaling
pathways. An excessive increase in ROS is cytotoxic to the cell, which results in cell death or
senescence. ROS generators include oxidases, oncogenes, hypoxia, and increased mitochondrial
activity, while ROS scavengers include SODs, Nrf2, Catalase, GSH/GPx, and HO-1.
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Figure 1.3. Nrf2 Activation
The nuclear factor erythroid 2-related factor (Nrf2) is a transcription factor that functions as the
key controller of the redox homeostatic gene regulatory network. Under oxidative and electrophilic
stresses, the Nrf2 signaling pathway is activated to enhance the expression of a multitude of
antioxidant and phase II enzymes that restore redox homeostasis. Kelch-like ECH-associated
protein 1 (Keap1) interacts with Nrf2, acting as an adaptor protein for the Cul3-dependent E3 (Cul3)
ubiquitin ligase complex. Under normal conditions, Keap1 promotes ubiquitination and
degradation of Nrf2. The many cysteine residues in the amino acid sequence of Keap1 enable it to
act as a sensor, detecting changes in cellular redox state. An increase in intracellular ROS results
in an increase in the oxidation of key Keap1 cysteines, which reduces its activity as an E3 ligase
adaptor. Thus, during cellular stress, Keap1 is less effective at promoting Nrf2 degradation. Upon
release from Keap 1, Nrf2 enters the nucleus where it activates transcription of cytoprotective
genes, including the components of an antioxidant system that can balance high ROS levels.
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Figure 1.4. Signaling Pathways Regulated by ROS
Many cellular processes produce O2•-, including cytosolic xanthine oxidase, the ETC, and NOX
enzymes. O2•- produced by membrane-bound NOXs can act both intra- and extracellularly.
H2O2 produced by SOD3 outside the cell can transverse into the cell interior in part through
aquaporin channels to initiate intracellular signaling, whereas O2•- could influx through the chloride
channel-3. The intracellular NOX complexes produce ROS where it acts locally. H2O2 has been
implicated in ROS signaling through oxidative modification of critical redox-sensitive Cys in
signaling proteins. The relatively well-recognized targets of ROS signaling include PTPs, PTKs,
PKC, MAPKs, and transcriptional factors. O2•- was shown that mitochondrial ROS act by signaling
in part through the intrinsic apoptotic pathway, likely via H2O2, triggering processes that promote
longevity.
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Figure 1.5. Dynamic Balance of ROS in Prostate Cancer
Diagram of the balance of ROS in PCa. Cells begin as benign epithelium, often in senescence. PCa
cells are documented to have higher levels of ROS than benign tissue. AS PCa cells have moderate
levels of ROS, which can be reduced by NAC treatment or antioxidants to bring about a milder
phenotype, or increased via H2O2 or pro-oxidants to promote PCa tumorigenicity and thus, more
aggressive cancer. AI PCa has even higher levels of ROS than AS PCa cells, which can also be
manipulated in a similar manner. Antioxidants and H2O2 can bring the cancer cells into an optimal
zone for tumorigenicity while increasing ROS levels can cause cytotoxicity and apoptosis.
Interestingly, p66Shc overexpression and subsequent ROS generation and enhance PCa
tumorigenicity, while loss of antioxidant molecules, such as HO-1 promote cell death.
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Chapter 2

Materials and Methods
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2.1 Materials
RPMI

1640

medium,

Keratinocyte

SFM

medium,

DMEM

medium,

2’,7’–

dichlorofluorescin diacetate (DCFDA), gentamicin, anti-p66Shc (#180S0105A) Ab, rhodamine
phalloidin, and L-glutamine were purchased from Invitrogen (Carlsbad, CA). FBS and charcoaltreated FBS were obtained from Atlanta Biologicals (Lawrenceville, GA). Molecular biology-grade
agarose and BRFF-HPC1 medium was procured from Fisher Scientific (Fair Lawn, NJ). Protein
molecular weight standard markers, acrylamide, and Bradford protein assay kit were purchased
from Bio-Rad (Hercules, CA). Docetaxel was purchased from Aventis Pharmaceutical Products
Inc. (Collegeville PA). Anti-AR (#C1411, 1:400), Anti-CDC25B (#D2810, 1:1000), anti-cyclin B1
(#K1907, 1:1000), anti-cyclin D1 (#A2712, 1:1000), anti-BclXL (#F111, 1:1000), anti-Bax (#G241,
1:1000), anti-PCNA (#G261, 1:3000), anti-p53 (#K2607, 1:1000), anti-PSA (#E1812, 1:2000),
anti-Survivin (#C271, 1:2000), anti-phospho-ErbB-2 (Y1221/2) (#B2212, 1:1000), anti-ErbB-2
(#E3110, 1:1000), anti-p42/p44 (#H1109, 1:1000), anti-Cyclin D1 (M-20, 1:1000), anti-PAcP
(#D0209, 1:1000), anti-PYK2 (#F061, 1:1000), anti-Rac1 (#G1905, 1:1000), and horseradish
peroxidase-conjugated anti-mouse (#C2011, 1:5000), anti-rabbit (#D2910, 1:5000), and anti-goat
(#J0608, 1:5000) IgG Abs were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Antiphospho-AKT (Ser473) (#GA160, 1:1000), anti-AKT (#C1411, 1:2000), anti-FOXM1 (#5436S,
1:500), anti-HA-Tag (#C29F4, 1:3000), anti-phospho-mTOR Ser2448 (#5536S, 1:1000), antimTOR (#2972S, 1:1000), anti-phospho-p42/p44 (#9101S, 1:1000), anti-Caspase 3 (#9665S,
1:1000), anti-PARP (#9532S, 1:1000) Abs were from Cell Signaling Technology (Beverly, MA).
Anti-HO-1 (#Z04608d, 1:1000) Ab was obtained from ENZO Life Sciences (Farmingdale, NY).
Anti-Nrf2 (ab62352, 1:1000) Ab was obtained from Abcam (Cambridge, UK). Anti-GTP-Rac1
(#G052YWF2, 1:1000) Ab was obtained from New East Biosciences (Malvern, PA). Antiphospho-PYK2 Y402 (#CDRO0114121, 1:1000) and anti-Catalase (#AF3398, 1:2000) Abs were
obtained from R&D Systems (Minneapolis, MN, USA). Anti-Shc (#06-203, 1:5000) Abs were
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obtained from Upstate Biotech. Inc. (Lake Placid, NY). Anti-Nrf2 (ab62352, 1:1000) Ab was
purchased from Abcam. Anti- HO-1 (ADI-OSA-110-F, 1:1000) antibody was purchased from Enzo
Biologicals. Anti-β-actin (#99H4842, 1:10000) Ab, N-acetyl-cysteine (NAC), hydrogen peroxide
(H2O2), DHT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetraazolium bromide (MTT) and
propidium iodide (PI) were procured from Sigma (St. Louis, MO). DAPI Hard-Mount Medium was
obtained from Vector Laboratories (Burlingame, CA). Enhanced chemiluminescence (ECL)
reagent kit was purchased from Thermo Scientific (Waltham, MA).
2.2 Cell Culture
Human prostate carcinoma cell lines LNCaP, MDA-PCa2b, VCaP, and PC-3, and immortalized
prostate epithelial RWPE-1 cells were originally purchased from the American Type Culture
Collection (Rockville, MD, USA). LNCaP and PC-3 were routinely maintained in RPMI 1640
medium containing 5% FBS, 2 mM glutamine, and 50 µg/ml gentamicin [131-134]. MDA PCa2b
cells were maintained in BRFF-HPC1 medium containing 20% FBS, 2 mM glutamine and 50 µg/ml
gentamicin [135,136]. VCaP cells were maintained in DMEM medium containing 15% FBS, 2 mM
glutamine, 50 µg/ml gentamicin, and 10 µg/ml ciprofloxacin [137,138]. RWPE-1 cells were
maintained in keratinocyte-SFM medium containing 25 μg/ml bovine pituitary extract and 0.15
ng/ml recombinant epidermal growth factor [139]. As reported previously, we established LNCaPAI (C-81), VCaP-AI, and MDA-AI cells, which obtain many biochemical properties of clinical CR
PCa including the expression of functional AR as well as PSA secretion and rapid cell proliferation
in androgen-depleted conditions [131-134,137]. Interestingly, passaging of these cells results in the
AI phenotype; after about 100 passages, these cells obtain the ability to growth in steroid-reduced
(SR) conditions [131-134,137]. LNCaP-AI cells also possess the enzymatic capacity to synthesize
androgens from cholesterol, one mechanism by which these cells have utilized to obtain the CR
phenotype. Most importantly, both AI cell lines have elevated basal growth rates as well as
increased levels of p66Shc protein compared to their respective AS cell lines [131]. To mimic
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conditions of clinical ADT, cells were maintained in SR conditions, i.e., phenol red-free RPMI
1640 medium containing 5% charcoal/dextran-treated FBS, 2 mM glutamine, 50 µg/ml gentamicin,
and 1 nM DHT. CIL-102 derivatives were synthesized by our collaborators at Kaohsiung
University (Taiwan). These compounds were dissolved in DMSO at 10 mM stock concentrations,
stored at -20°C and diluted as needed for experimental conditions in the respective medium.
2.3 Immunoblot Analysis
All cells were rinsed with ice-cold HEPES-buffered saline, pH 7.0, harvested via scraping, and
lysed in ice-cold lysis buffer containing protease and phosphatase inhibitors. Total cellular lysates
were prepared as previously described [136,138,139]. The protein concentration of the supernatant
was determined using a Bio-Rad Bradford protein-assay. For immunoblotting, an aliquot of total
cell lysate was electrophoresed on SDS-polyacrylamide gels (7.5%-12%). After being transferred
to nitrocellulose membrane, the membrane was blocked with 5% non-fat milk in Tris-buffered
saline containing 0.1% Tween-20 for 30 minutes at room temperature. Membranes were incubated
with the corresponding primary Ab overnight at 4°C. Membranes were then rinsed and incubated
with the appropriate secondary Ab for 60 minutes at room temperature. Proteins of interest were
detected by an ECL reagent kit and β-actin was used as a loading control. The intensity of the
protein bands was analyzed with ImageJ software (NIH, Bethesda, MD) [135,139-141].
2.4 MTT Assay
For the MTT assay, LNCaP C-81, VCaP-AI, PC-3, and RWPE-1 cells were plated at 1.5 x 104, 7
x 104, 1 x 103, and 7.5 x 104 cells per well, respectively, in 96 well plates in SR conditions for 24
hours. Cells were then treated with 1 μM of each of the CIL-102 derivatives in SR medium for 72
hours. 1 mM MTT solution was added to the cells and incubated at 37 ⁰C for 4 hours.

Dimethylsulfoxide (DMSO) was added to the reaction and incubated for 10 minutes at 37 ⁰C. The
absorbance was measured at 540 nm using a Molecular Devices SpectraMax 190 [139].
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2.5 Trypan Blue Exclusion Assay
For cell proliferation experiments under regular conditions, cells were seeded in regular culture
medium and allowed to attach for 3 days, then changed to fresh medium containing the respective
statin compounds and cultured for an additional 3 days. To determine cell proliferation under SR
conditions, all cells were seeded in regular conditions and allowed to attach for 3 days. Cells were
then steroid-starved for 48 hours in SR medium and changed to fresh SR medium containing the
noted compound(s) and cultured for an additional 3 days. Control groups received solvent DMSO
alone. Cells were harvested via trypsinization, and live cell numbers were counted by Trypan Blue
dye exclusion assay using a Cellometer Auto T4 Image-based cell counter (Nexcelom, MA, USA)
according to previous publications [139-141].
2.6 Clonogenic Assay
The clonogenic cell growth assay was conducted as described previously [139,140,142,143].
Briefly, LNCaP-AI cells were plated on the plastic surface of 6-well plates under regular culture
conditions at a density of 2,000 cells per well. Cells were incubated overnight, the unattached cells
were removed, and remaining cells were fed with fresh regular medium. Cells were grown for 9
days with a change of fresh medium every 3 days. On the 10th day, the medium was removed, and
cells were washed with ice-cold HEPES-buffered saline, then attached cells were stained with a
0.2% crystal violet solution containing 50% methanol and colonies of over 50 cells were
enumerated.
2.7 Soft Agar Assay
The effect of the CIL-102 derivatives on anchorage-independent LNCaP-AI colony growth was
assessed by soft agar assay. Briefly, 5 x 104 cells were seeded into a 0.25% agarose top layer with
a base layer containing 0.3% agarose in 35mm dishes. The day after seeding, cell clusters
containing more than one cell were excluded from the study. Cells were then fed with 0.5 mL of
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fresh regular medium containing the respective CIL-102 derivative every 3 days for 6 weeks. The
colonies were then stained with a 0.2% crystal violet solution containing 50% methanol and
colonies of roughly 100 cells were counted [139].
2.8 Boyden Chamber Transwell Assay
Cell migration was assessed via Boyden Chamber transwell assay as described previously
[143,144]. Cells were plated at a density of 5 x 104 cells into the upper chamber of 24-well plate
transwell inserts and allowed to migrate for 24 hours. In experiments with small molecule
inhibitors, inhibitor compounds were added to the bottom chamber for a final concentration of their
IC50 in LNCaP cells prior to the addition of cells. After a 24-hour incubation, cells were stained
with 0.2% crystal violet solution in 50% methanol, and remaining cells in the upper chamber were
removed via cotton swab. Cells which had migrated to the lower chamber were counted at 40x
magnification under a microscope. For experiments using small molecule inhibitors, to distinguish
cell migration from cell growth, the results were normalized to growth inhibition in which the 24hour change in cell migration was divided by the 24-hour change in cell growth.
2.9 Flow Cytometry Analysis
2.9.A. DCF-DA Assay
Changes in cellular ROS levels induced by statin-compounds in LNCaP-AI cells were determined
via DCF-DA dye analysis [141]. Cells were plated in triplicate at a density of 2 x 104 cells per well
using 6-well plastic plates and grown under regular conditions for 3 days. Cells were then steroid
starved for 48 hours in SR medium before being changed to fresh SR medium containing the noted
treatment compound(s) and cultured for an additional 3 days. Control groups received solvent
DMSO alone. Cells were harvested and incubated with medium containing 20 µM DCF-DA dye.
2.9.B. Propidium Iodide Assay
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To determine the effects on cell cycle, flow cytometry analysis was conducted as previously
described [139,141]. Briefly, LNCaP-AI cells were seeded in T25 flasks at a density of 5 x 104 cells
in regular medium for 3 days, changed to SR medium for 48 hours, and then fed with fresh SR
medium containing 20 µM of the specified compound. Cells were harvested after 3 days of
treatment, fixed with 70% ethanol, and stained using Telford Reagent at 4°C for 4 hours [139,145].
Determination of cell cycle distribution and DCF-DA fluorescence was carried out using the
Becton-Dickinson fluorescence-activated cell sorter (FACSCalibur, Becton Dickinson, San Jose,
CA, USA) at the UNMC Flow Cytometry Core Facility [139,141].
2.10 Computational Modeling
We analyzed the 3D putative binding of small molecular compounds to tubulin. The 3D
computational analysis on 1-Click Docking online by mcule (https://mcule.com/) was utilized for
3D modeling of CIL-102 derivative binding to the tubulin dimer. Models were based on a reported
electron crystallography model from the Protein Data Bank (PDB) (PDB ID: 1TUB). CIL-102 and
its derivatives 1, 22, and 23 were drawn in 2D, then converted to 3D via OpenBabel, followed by
conversion to pdbqt format via AutoDock Tools. Docking (Vina) scores are a rough estimation of
the binding affinity. A more negative score suggests a higher binding affinity. The α/β-tubulin
dimer (1TUB) was uploaded from PDB, upon which the binding site center was chosen. Analysis
of all noted amino acid residues for CIL-102 binding to tubulin from Gireesh et al. [146] was
performed with the original compound, CIL-102. Binding scores lower than -9.0 were excluded
due to the molecule binding internally within the protein. The best remaining score, in which the
CIL-102 molecule was bound at the colchicine binding site, was calculated with the binding site
center located at the Cys-356 residue, coordinates X:-64.769, Y:39.721, Z:-29.03. 1, 22 and 23
compounds were also analyzed for their binding score at the same Cys-356 residue.
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An analysis was also performed with an alternative binding site for CIL-102 found utilizing Vina
docking. Analysis of binding of the three CIL-102 derivatives was carried on using residue Asn197,
coordinates X:-75.905, Y:57.052, Z:-39.159 [139].
2.11 Protein Microarray
Cell lysates were prepared from an equally mixed population of stable p66Shc cDNA-transfected
subclones and V1 vector-alone control cells as previously described and sent to Kinexus Protein
Profiling Services (Vancouver, BC) where the company performed analysis via the KAM-900P
microarray. Results are reported in the format of percent change from control (%CFC) using Zscore transformation [141].
2.12 Immunofluorescence and Confocal Microscopy
Cells were plated on sterile round coverslips at 3x104 cells per coverslip and allowed to attach for
24 hours. Cells were then washed with pre-warmed phosphate-buffered saline and fixed with a
3.7% formaldehyde solution for 10 minutes at room temperature. Cells were then washed,
permeabilized with 0.1% Triton X-100 solution for 5 minutes, and again washed before blocking
with 1% BSA solution for 30 minutes. At this time, cells were stained with fluorescent indicators
MitoSOX and Peroxy Orange-1, which bind to mitochondrial superoxide and hydrogen peroxide
respectively, in 1% BSA for 20 minutes followed by washing. To stain cells for α-tubulin, oxidized
cystiene, or 8-hydroxyguanosine, cells were incubated with their respective primary Abs in 1%
BSA for 1 hour, followed by washing and secondary Alexa Fluor 680 mouse Ab incubation for 30
minutes and a final wash. Coverslips were then mounted using VectorShield hard-mount medium
containing DAPI stain and allowed to set overnight before images were captured via confocal
microscopy [140]. The relative area of fluorescence to total cell area was semi-quantified using
NIH ImageJ software. Results were repeated in three separate experiments in which 20 cells were
quantified (For a total of 60) for each cell-line/treatment [141].
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2.13 cDNA, shRNA, and siRNA Transfection
For transient transfection experiments, LNCaP cells were plated at a density of 1x104 cells per cm2
and transfected using Lipofectamine and Plus reagents (Thermo Fisher, Waltham, MA). Five hours
after transfection, the cells were fed with RPMI medium containing 10% FBS for 24 hrs. The cells
were then used for transwell assays and whole cell lysates harvested for immunoblot analysis.
Stable subclones of LNCaP cells overexpressing p66Shc were established as described previously
[131]. For knock-down of p66Shc expression, transient transfection of pSUP-p66 plasmid-based
small interfering RNA system targeted against the CH2 domain was used for cDNA transfection
as described previously [131,139,141]. Competitive inhibition of p66Shc ROS-production activity
was achieved upon transfection of cells with p66Shc W134F redox inactive mutant cDNA [67].
2.14 Implantation of Tumor Cells and Bio-luminescence Imaging
For the orthotopic implantation, athymic mice were anesthetized by a continuous flow of 2.5%
isoflurane with oxygen using a mouse anesthesia machine. LNCaP-AS, LNCaP-AI, LNCaP-AILuc, V1, or p66Shc subclone cells (50 μl containing 2.0 x 106 cells in 50% Matrigel) were injected
into the dorsal prostatic lobe using a 30-gauge needle. The peritoneal tissues were closed in two
layers with absorbable catgut sutures (563B, Surgical Specialties, Tijuana, Mexico). Buprenorphine
(0.1 mg/kg, Reckitt Benckiser Healthcare (UK) Ltd., Hull, England) was administrated by
intraperitoneal route immediately after the surgery followed by three doses at six, twenty-four and
forty-eight hours after surgery. Sterile surgical procedures were maintained for the entire process
[147]. For subcutaneous tumor implantation, 1x 106 cells (200 μl with 50% Matrigel) were injected
into the dorsal surface of the mice via a 26-gauge needle [147].
LNCaP-AI-Luciferase-inoculated mice were imaged at three or five weeks after surgery. For
imaging, D-Luciferin potassium salt (100 mg/kg, PerkinElmer, #122799, Waltham, MA, USA) was
dissolved in sterile PBS and injected intraperitoneally into the tumor-bearing mice 15 minutes prior
to imaging. For imaging the luciferase-expressing tumors, mice were anesthetized using 2.5%
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isoflurane with oxygen and placed in the Xenogen IVIS Spectrum bioluminescence imaging system
(PerkinElmer, MA, USA). Images were acquired and analyzed by Living Image 4.5.1 software
(Caliper Life Sciences, MA, USA) with an exposure time of one second. Regions of interest (ROI)
were determined to encompass the area with the most intense light, and signal intensity was
calculated based on a measurement of photons/s/cm2/sr [147].
2.15 Statistical Analysis
Each set of experiments are conducted in triplicate or duplicate as specified in the figure legend,
and experiments are repeated at least three times independently, denoted as n=3x3. All results are
presented as mean ± standard error measurement of the mean. Correlation coefficient r was
calculated using Microsoft Excel. Statistical significance was determined using a paired two-tailed
student-t-test assuming unequal variance where appropriate unless otherwise stated. p<0.05 was
considered statistically significant.
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Chapter 3
p66Shc/ROS Enhances the Progression of Androgen-Sensitive Prostate
Cancer Cells Towards Castration-Resistance

This chapter is derived from:
Miller DR, Ingersoll MA, Chatterjee A, Chang PW, Oberley-Deegan RE, Lin MF. p66Shc/ROS
Enhances the Progression of Androgen-Sensitive Prostate Cancer Cells Towards CastrationResistance. Under Revision.
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3.1 Synopsis
Prostate cancer (PCa) remains the second leading cause of cancer-related deaths in U.S. men due
to the development of castration-resistant (CR) PCa. A useful cell model for analysis of the
molecular mechanism of PCa progression is required for developing targeted therapies for CR PCa.
In this study, we established a PCa cell progressive model in three independent cell lines, of which
androgen-independent (AI) cells were derived from respective androgen-sensitive (AS) cells. AI
PCa cells have enhanced tumorigenicity recapitulating the clinical phenotype of CR PCa, including
AR expression, proliferation, and tumorigenicity under androgen-deprived conditions. Further, AI
cells exhibit increased ROS levels as well as enhanced signaling of proliferation and survival
pathways. We further identified p66Shc oxidase as one of the potential sources of ROS-mediated
phenotype and cell signaling alterations in AI PCa cells. LNCaP-AI cells and p66Shc subclones
have a greater oxidative environment compared to LNCaP-AS cells. Increased ROS via H2O2
enhanced AS cell growth and migration, which was counteracted by the antioxidant N-acetyl
cysteine (NAC). Treatment of LNCaP-AS cells with H2O2 resulted in a similar signaling profile to
that of LNCaP-AI or p66Shc subclone cells. Further, the ROS-driven alterations of LNCaP-AI and
p66Shc subclone cell signaling can be mitigated via p66Shc knockdown. Moreover, LNCaP-AI
cells and p66Shc subclones, but not LNCaP-AS cells, develop xenograft tumors with metastatic
nodules further demonstrating the CR phenotype. Together, the data show ROS produced by
p66Shc promotes PCa tumorigenicity and progression to the CR phenotype.
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3.2 Background and Rationale
After initial ADT, there is a high likelihood of relapse and development of castration-resistant (CR)
PCa. Currently, there are no effective therapies currently available for patients with CR PCa, and
several FDA-approved agents, such as docetaxel, can only extend the patient’s life by a few months
[148]. Therefore, we investigated the molecular mechanism of CR PCa progression to identify the
novel target(s) for developing alternative therapies to treat this lethal disease.
Reactive oxygen species (ROS) play a vital role in diverse cell signaling and apoptosis. ROS
molecules are natural byproducts of cellular respiration and contribute to essential signaling
pathways; local ROS production stimulated by external growth factors and hormones is an
important source of signal transduction through the oxidation and reduction of proteins
[24,68,87,88,149]. ROS can thus regulate diverse processes such as angiogenesis, cell adhesion,
proliferation, and migration, all of which are critical to cancer progression [7,91,99,108,151].
Results of several studies have shown that oxidation of protein tyrosine phosphatases via increased
cellular ROS levels can inhibit its enzymatic activity; thus, leaving kinase activity unregulated,
which results in the promotion of cell proliferation and migration [68,71,90] and the progression
of cancers, including PCa [96]. For example, the protein levels of several NADPH oxidases (NOXs)
increase upon progression to the CR phenotype in PCa tissues and cell lines [24,94,152].
Additionally, ROS has been shown to promote PCa proliferation, migration, invasion, and
metastasis [24], and activation of AR can result in increased ROS generation, in part, due to
augmented mitochondrial activity [103,153,154]. While there are many studies on the correlative
influence of ROS on PCa progression, the effects of ROS and its molecular mechanism by a specific
functional molecule on PCa progression remain unclear.
In this study, we established a PCa cell progression model including LNCaP, MDA PCa2b, and
VCaP PCa cell lines and investigated the role of ROS in androgen-sensitive (AS) and androgenindependent (AI) PCa tumorigenicity. In this progressive cell model, AI PCa cells have enhanced
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proliferative activity in steroid-reduced (SR) conditions as well as increased migratory and colony
formation ability, and ROS levels. Interestingly, treatment of AS cells with H2O2 increases cell
growth and migration, which was counteracted by treatment with antioxidant N-acetyl-cysteine
(NAC). Furthermore, our studies revealed that in AI PCa cells, there were increased protein levels
of p66Shc, which promotes both mitochondrial superoxide production and activation of NOX
complexes via Rac1 to increase cellular ROS levels and enhance activation of survival, growth,
and migration pathways [141]. Additionally, LNCaP-AI cells and p66Shc subclones, but not
LNCaP-AS cells, are able to metastasize upon orthotopic implantation in nude mice. Together, this
data demonstrates the ability of increased ROS levels to promote AS PCa tumorigenicity. Further,
the pro-oxidant p66Shc plays a critical role in ROS-mediated PCa progression.

3.3 Results
3.3.1 Proliferation of AS and AI PCa Cells in Regular and SR Conditions
To demonstrate the AI phenotype, we analyzed the proliferation of AS PCa cells and the
corresponding AI counterparts in both regular steroid-containing and SR conditions via trypan blue
exclusion assay. Proliferating Cell Nuclear Antigen (PCNA), a proliferative marker, was analyzed
by western blotting. In regular culture conditions that contain androgenic activity, LNCaP-AI,
MDA PCa2b-AI, and VCaP-AI cells have rapid growth rates, higher than the corresponding
LNCaP-AS, MDA PCa2b-AS, and VCaP-AS cells (Fig. 3.1A-C). Western blot analyses showed
that AI cells have higher levels of PCNA compared to their AS counterparts. In SR conditions, the
differential growth rates were even more pronounced because AS cells have dramatically reduced
proliferative ability in androgen-deprived conditions, while AI cells retain their rapid growth rates
(Fig 3.1D-F). Nevertheless, it should be noted that while AI cells proliferate well in SR conditions,
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the growth rate is reduced compared to regular conditions. In summary, all three AI cells proliferate
rapidly in SR conditions.

3.3.2 Colony Formation and Migration of AS and AI PCa Cells
The tumorigenicity of AS and AI cells were analyzed by clonogenic and Boyden chamber transwell
assays. LNCaP-AI, MDA PCa2b-AI, and VCaP-AI cells had increased colony formation and
migration as compared to their respective AS counterparts. LNCaP-AS cells formed an average of
50 colonies compared to 214 LNCaP-AI colonies (Fig. 3.2A). MDA PCa2b-AS and VCaP-AS cells
grew 30 and 35 colonies, respectively, while their AI counterparts formed 338 and 172 colonies
(Fig. 3.2B and 3.2C). In the Boyden chamber transwell assay, LNCaP-AI cells migrated at
approximately 2-fold faster rates after 24 hours compared to LNCaP-AS cells (Fig. 3.2D). MDA
PCa2b-AI and VCaP-AI cells have migratory rates about 3-fold and 4-fold of the MDA PCa2b-AS
and VCaP-AS cells, respectively (Fig. 3.2E and 3.2F). Thus, the tumorigenicity of AI cells
increases as compared to the corresponding AS cells.

3.3.3 Basal ROS Levels and ROS-Sensitive Cell Signaling Profiles in AS and AI PCa Cells
Because ROS levels have been proposed to play a role in PCa progression [24,97,103] we semiquantified the relative basal ROS levels in AS and AI PCa cells utilizing DCF-DA dye. As shown
in Fig. 3.3A, a significantly greater amount of fluorescence was detected in LNCaP-AI cells
compared to LNCaP-AS cells. Similarly, MDA PCa2b-AI (Fig. 3.3B) and VCaP-AI (Fig. 3.3C)
cells had significantly higher basal levels of ROS compared to corresponding AS cells. On average,
AI PCa cells had about 40% higher basal ROS levels than their respective AS PCa cells.
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Western blot analysis was conducted to analyze the cell signaling profile focusing on ROS-related
signaling in our PCa progressive cell model (Fig. 3.3D). Among three Shc family members,
p66Shc, an authentic oxidase, was elevated in LNCaP-AI, MDA PCa2b-AI, and VCaP-AI cells
compared to their AS counterparts; while the protein levels of the other two Shc isoforms, p52Shc
and p46Shc, were not significantly altered in the respective AI cells (Fig. 3.3). While AR protein
levels showed only a minor change in the three progressive cell lines, cellular PSA (cPSA), an
androgen-regulated biomarker in PCa cells, was greatly elevated in AI PCa cells, indicating AR
activation [131]. Cellular Prostatic Acid Phosphatase (cPAcP), a negative growth regulator of PCa
cells [136,156], was more readily reduced in LNCaP-AI and MDA PCa2b-AI cells, while there
was only a minor change in VCaP-AI cells compared to VCaP-AS cells (the 50kDa protein is the
active form of PAcP, while the 37 kDa protein is the intermediate form). Importantly, in all three
AI PCa cells, there were increased phosphorylation levels of ErbB-2, AKT, ERK, and mTOR when
compared to their AS counterparts. ROS-sensitive FOXM1 and its downstream targets CDC25B
and Cyclin B1 were increased upon progression to the AI phenotype. There were also increased
phosphorylation of PYK2 and elevated levels of P-Rex1 and GTP-bound Rac1, the activated form
of Rac1, in AI PCa cells, both critical proteins involved in cell migration. In summary, the signaling
profile in these three PCa cell progressive models demonstrates that ROS-sensitive signaling is
altered and AI PCa cells have more significant potential for cell survival, proliferation, and
migration compared to corresponding AS PCa cells.

3.3.4 Effects of ROS by H2O2 and NAC on AS PCa Cell Proliferation and Migration
Because ROS is proposed to play a role in clinical PCa progression and ROS levels are elevated in
AI PCa cells compared to respective AS PCa cells (Fig. 3.3), we analyzed the direct effects of H2O2
and NAC, a precursor to H2O2 scavenger glutathione, on AS PCa cell growth and migration. The
effects of ROS in the form of H2O2 at the physiological level on cell growth was initially performed
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with LNCaP-AS cells as a model system (Fig. 3.4A), which demonstrated that 5 μM of H2O2
promotes a significant increase in cell growth, with 10 μM producing the optimal effect on cell
growth. Conversely, NAC treatment reduced the basal cell growth and counteracted H2O2stimulated cell proliferation (Fig. 3.4A).
H2O2 (10 μM) treatment led to the optimal increase in cell proliferation of LNCaP-AS cells;
therefore this concentration was utilized for H2O2 treatments throughout the rest of the study. H2O2
(10 μM) treatment increased MDA PCa2b-AS cell growth by about 80%, while NAC (10 mM)
treatment reduced the basal cell proliferation by an average of 50% (Fig. 3.4B). The combination
of NAC abolished the stimulatory effect of H2O2 treatment on cell proliferation of MDA PCa2bAS cells (Fig. 3.4B). A similar trend was seen in VCaP-AS cells in which H2O2 treatment increased
cell proliferation, while NAC treatment effectively reduced both basal and H2O2-stimulated cell
proliferation (Fig. 3.4C).
H2O2 and NAC treatments exhibited similar effects on cell migration in all three AS cell lines
observed in cell proliferation. H2O2 (10 μM) treatment increased cell migration by about 70%, 30%,
and 50% in LNCaP-AS, MDA PCa2b-AS, and VCaP-AS cells, respectively; NAC (10 mM)
treatment reduced migration to below basal levels. Further, NAC reduced H2O2-enhanced
migration by about 30-50% compared to control cells (Fig. 3.4D-3.4F).
The effects of H2O2 and NAC treatments on cellular H2O2 levels were examined in LNCaP-AS
cells as the model system. LNCaP-AS cells were stained with Peroxy Orange-1 (PO-1) to detect
H2O2 levels. In LNCaP-AS cells, H2O2 (10 μM) treatment significantly increased H2O2 levels by
about 50%, while NAC (10 mM) treatment resulted in a 20% reduction of basal H2O2 levels.
Concurrent treatment with H2O2 and NAC could effectively abolish the effects of H2O2 on the
cellular oxidative environment (Fig. 3.4G). Thus, cellular levels of ROS/H2O2 change correlating
with H2O2 and NAC treatments resulting in altered cell proliferation and migration.
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3.3.5 Cell Growth and Cellular Levels of ROS in LNCaP-AS and LNCaP-AI Cells and p66Shc
Subclones
Because p66Shc protein levels are elevated in all three AI cells (Fig. 3.3D), we determined the
effect of p66Shc on cell growth (Fig. 3.5A and 3.5B) and analyzed general ROS (DCF-DA), H2O2
(PO-1) and mitochondrial superoxide (MitoSOX) levels in LNCaP-AI cells as well as p66Shc
subclones versus V1 control cells. Comparing LNCaP-AI cells transfected with p66Shc shRNA to
control cells, there was a 60% reduction in cell proliferation (Fig. 3.5A). Upon stable transfection
of LNCaP-AS cells with p66Shc cDNA, there was a 140-150% increase in cell proliferation
compared to vector-alone V1 control cells, while there was a 60% reduction in cell proliferation in
the stable p66Shc subclones upon knockdown of p66Shc (Fig. 3.5B). Interestingly, DCF-DA
analysis demonstrated that knockdown of p66Shc in both LNCaP-AI cells as well as p66Shc
subclones resulted in a 40% reduction in general ROS levels (Fig. 3.5C and 3.5D). As shown in
Figure 5E, comparing the basal H2O2 levels in LNCaP-AS with LNCaP-AI cells, H2O2 levels are
50% greater in AI cells than AS cells and about 75% greater in p66Shc subclones compared to V1
control cells transfected with the vector alone. Importantly, transfection of LNCaP-AI cells or
p66Shc subclones with p66Shc shRNA resulted in a decrease in PO-1 staining to that of basal levels
seen in LNCaP-AS cells or V1 vector-alone transfected cells (Fig. 3.5E). Furthermore, MitoSOX
fluorescence in LNCaP-AI cells was about 5-fold greater than in LNCaP-AS cells. Similarly,
p66Shc subclones had an average of 3.5-fold greater mitochondrial superoxide levels compared to
control cells transfected with the vector alone. Similar to PO-1 staining, upon transfection with
p66Shc shRNA, MitoSOX fluorescence was reduced to that of LNCaP-AS or V1 cell levels in
LNCaP-AI and p66Shc subclones (Fig. 3.5F). Therefore, increased p66Shc protein levels in both
LNCaP–AI cells and p66Shc stable subclones are associated with a significant increase in H2O2
and mitochondrial O2- levels, correlating with the AI phenotype.
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3.3.6 Cell Signaling Profile in LNCaP Cells and p66Shc Subclones
To identify the common functional molecules in CR PCa progression, LNCaP cells and p66Shc
subclone cell lysates under regular culture conditions were analyzed for alteration of
phosphoproteins by Kinexus. Figure 3.6 shows that several functional proteins with elevated
phosphorylation levels are consistent between LNCaP-AI cells and p66Shc subclones. For
example, phosphorylation levels of ABL1, ACK1, AKT2, AKT3, AMPKα2, ANKRD3/RIPK4,
APP, EGFR, ErbB2, ErbB3, MET, and mTOR were elevated. Nevertheless, p66Shc subclones had
an increase in phosphorylation of MAPKs including ERK2 and ERK5, MKK2, and MEKK2, as
well as activation of PKC and cyclin-dependent kinases CDK1, CDK4, CDK10, and CDK12.
Together, the data show several signaling pathways, such as MET, ABL1, and the ErbB family, are
activated in both LNCaP-AI cells and p66Shc subclones, suggesting that these pathways are altered
upon progression to the AI phenotype with increased ROS levels.
Additionally, we performed molecular profiling on ROS-sensitive functional molecules by Western
blot analysis (Fig. 3.7). LNCaP-AS cells were treated with H2O2 (0-20 μM), NAC (10 mM), or a
combination of H2O2 (10 μM) and NAC (10 mM) for 48 hours. While there was an apparent
increase in p66Shc protein levels upon treatment with H2O2, the protein level was still quite low.
This suggests that p66Shc expression and/or protein levels is not positively regulated by ROS.
There were no significant changes in AR or cPSA protein levels. cPAcP protein levels were reduced
upon H2O2, NAC, or the combination treatment. Further, cell proliferation and survival proteins
ErbB-2, AKT, ERK, and mTOR had elevated phosphorylation levels with increasing
concentrations of H2O2, which was counteracted by NAC. FOXM1 protein levels as well as
phosphorylated PYK2 and GTP-bound Rac1 increased with H2O2 treatment and countered by NAC
(Fig. 3.7A). Importantly, a similar signaling profile was seen in p66Shc subclones compared to
vector-alone transfected V1 cells. p66Shc protein levels were increased in the p66Shc subclones as
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well as enhanced phosphorylation of ErbB-2, AKT, ERK, mTOR, and PYK2 compared to V1 cells.
FOXM1 levels were also increased in p66Shc subclones. Interestingly, cPAcP levels were reduced
upon increased p66Shc expression (Fig. 3.7B). Further, knockdown of p66Shc in LNCaP-AI cells
and stable p66Shc subclones resulted in reduced p66Shc and FOXM1 protein levels and decreased
phosphorylation of ErbB-2, AKT, ERK, mTOR, and PYK2. Conversely, cPAcP levels were
increased, especially the 50 kDa form (Fig. 3.7B). The data demonstrate that these signaling
pathways are sensitive to ROS and that p66Shc is one source of ROS that could alter cell signaling
in PCa.

3.3.7 LNCaP Progressive Cell Model and p66Shc Subclones in Xenograft Mouse Models
We determined the effect of p66Shc expression on in vivo tumorigenicity in xenograft animals.
Initially, western blot analysis was utilized to determine protein levels of p66Shc in LNCaP-AS,
LNCaP-AI, V1 and p66Shc subclone cells. Immunoblot analysis revealed that LNCaP-AS cells
have the lowest levels of p66Shc, V1 and LNCaP-AI cells have moderate protein levels of p66Shc,
and p66Shc subclones have the highest protein levels of p66Shc among the cell lines examined
(Fig. 3.8A). To determine the in vivo tumor growth, these cells were subcutaneously injected into
female athymic mice with low circulating androgens to mimic castrated conditions. Under castrated
conditions in female mice, LNCaP-AS and V1 cells developed subcutaneous tumors in about 50%
of the animals; while LNCaP-AI and p66Shc subclone cells developed tumors in at least 80% of
the mice. LNCaP-AS and V1 tumors were in average about 193 mm3 and 144 mm3, respectively,
while LNCaP-AI and p66Shc subclone tumors both had sizes of about 800 mm3 (Fig. 3.8B). Thus,
LNCaP-AI and p66Shc-overexpressing subclones obtain the enhanced tumorigenicity by
developing more and larger tumors than AS cells in androgen-reduced environments, correlating
with p66Shc protein levels.
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To determine the effect of p66Shc expression on local invasion, LNCaP-AS and LNCaP-AI cells
underwent orthotopic injection into the prostates of male athymic mice. As shown in Fig. 3.8B, no
male mice developed metastatic tumors upon implantation with LNCaP-AS cells, while about 50%
of mice with LNCaP-AI tumors exhibited metastasis. Additionally, 40% of mice with V1 tumors
developed metastasis, while 100% of mice implanted with p66Shc subclone tumors developed
metastasis (Fig. 3.8B). Collectively, p66Shc protein levels correlate with the metastatic frequency
(Fig. 3.8A and 3.8B) with a linear correlation R-value of 0.8314. Figure 3.8C clearly shows that
orthotopic mouse models of LNCaP-AI-Luc cells develop metastatic tumors 3 weeks after
implantation; while Figure 8D shows the metastasized tumors of p66Shc subclones in the pancreas
and GI tract, which were the two most common metastasis locations (Fig 3.8E). Importantly, this
data clearly demonstrates that the metastatic ability of PCa tumors correlates with p66Shc protein
levels.
3.4 Discussion
CR PCa is a lethal disease that patients succumb to shortly upon development; thus, understanding
the mechanism of PCa progression from the AS to the AI/CR phenotype is crucial for developing
therapeutic options for this patient population. In this study, we report the establishment of a PCa
cell progression model in three PCa cell lines that replicate clinical PCa progression from the AS
to the AI phenotype. We further investigated the molecular mechanisms and determined that
p66Shc/ROS plays a vital role in PCa progression.
Results of trypan blue exclusion, Boyden chamber transwell, and clonogenic assays clearly show
that all three AR-positive AI cells, including LNCaP-AI, MDA PCa2b-AI, and VCaP-AI PCa cells,
have greater tumorigenicity than respective AS cells, including proliferation, migration, and colony
formation (Fig. 3.1 and 3.2). Importantly, in SR conditions, AI PCa cells retained the rapid cell
proliferation while the growth of AS PCa cells was arrested (Fig. 3.1). Further, AI PCa cells have
higher levels of ROS than AS cells (Fig. 3.3A-3.3C), and AI cells have activated survival,
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proliferation, and migration pathways (Fig. 3.3D). Significantly, activation of these pathways is
seen in clinical advanced PCa, such as AKT [155], ERK [156], mTOR [157], and P-Rex1 [158162]. Increased P-Rex1 protein and Rac1 activity further suggest that AI PCa cells have greater
migratory ability and potential for metastasis [160,162], as seen by the LNCaP-AI and p66Shc
subclone xenograft tumors in Figure 8. Thus, we have established a useful PCa cell progression
model in three AR-positive PCa cell lines that recapitulate disease progression seen in the clinic.
We also investigated the role of ROS in PCa progression including cell proliferation and migration
via H2O2 and/or NAC treatments on AS PCa cells. Interestingly, H2O2 treatments increased AS PCa
cell proliferation and migration, while NAC competitively counteracted H2O2-induced cell
proliferation and migration (Fig. 3.4). We further analyzed a specific functional oxidase molecule
that could be involved in the phenotypic alteration seen in AI PCa cells. p66Shc is an authentic
oxidase involved in PCa proliferation and migration and can promote the CR phenotype in AS PCa
cells [67,152,153]. LNCaP-AI cells and stable p66Shc subclones, which both exhibit the AI
phenotype [68], had higher oxidative environments compared to LNCaP-AS and V1 cells (Fig.
3.5). Furthermore, we saw a reduction in both hydrogen peroxide and mitochondrial superoxide
staining in both LNCaP-AI cells and p66Shc subclones upon p66Shc knockdown. A dramatic 4- or
5-fold decrease in mitochondrial superoxide, suggests that p66Shc provides a greater contribution
to the mitochondrial superoxide levels than cellular H2O2 levels, which were only reduced by about
40%. To elucidate the molecular signaling mechanism of AI PCa cells, we performed a
phosphoprotein microarray. Significantly, several proteins, including ABL1, AKT, ErbB-1/2/3,
MET, and mTOR, have enhanced activation in both LNCaP-AI cells and p66Shc subclones (Fig.
3.6). Our data further demonstrated ROS-mediated alterations in cell signaling profile with the
treatment of LNCaP-AS cells with H2O2 (Fig. 3.7), which was essentially identical to the AI PCa
signaling profile in Figure 3D. Treatment of LNCaP-AS cells with H2O2 led to activation via
increased phosphorylation of ErbB-2, AKT, ERK, mTOR, and PYK2 as well as GTP-bound Rac1.
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We further confirmed that there was increased phosphorylation of ErbB-2, AKT, ERK, mTOR, and
PYK2 in p66Shc subclones and that knockdown of p66Shc reduced the activity of these signaling
pathways (Fig. 3.7B). This confirms the study by Ingersoll et al. in which both p66Shc knockdown
and introduction of the p66Shc W134F redox-inactive mutant cDNA resulted in a reduction in
phosphorylation of these particular pathways [150]. Interestingly, many of these ROS-sensitive
proteins are involved in cell survival, proliferation, and migration such as MET, AKT [163], mTOR
[164], ACK1 [165], and ABL1 [166]. Lastly, we demonstrated the ability of LNCaP-AI cells and
p66Shc subclones, but not LNCaP-AS cells, to develop xenograft tumors in castrated conditions.
Further, LNCaP-AI cells and p66Shc subclones exhibit enhanced metastatic ability, which
correlates with p66Shc protein expression (Fig. 3.8). Our data together suggest that p66Shc could
serve as a functional target and novel small molecule inhibitors for p66Shc could be developed for
the treatment of CR PCa.
Figure 3.9 represents the working hypothesis for the role of ROS in PCa progression. Suboptimal
ROS levels result in cell senescence, while a moderate increase in ROS levels promotes an
environment in which cells exhibit the highest potential of proliferation, migration, and invasion.
AS PCa cells, including LNCaP-AS, MDA PCa2b-AS, and VCaP-AS PCa cells, can increase
protein levels of oxidases, such as p66Shc, or be treated with H2O2 to promote their tumorigenic
phenotypes, while NAC or antioxidant enzymes will reduce cell growth (Fig. 3.9A). Moreover,
increased ROS production via p66Shc can inactivate cPAcP, resulting in increased activity of
ErbB-2, AKT, ERK, mTOR, PYK2, and Rac1, promoting PCa proliferation and survival (Fig.
3.9B) [66,67,154].
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3.5 Figures

Figure 3.1. AS and AI PCa Cell Growth in Regular and SR Conditions.
AS and AI LNCaP, MDA PCa2b, and VCaP cells were subjected to a kinetic growth assay in
regular (A-C) and SR conditions (D-F). LNCaP (A and D), MDA PCa2b (B and E), and VCaP (C
and F) cells were plated at 2 x 104, 1 x 105, and 2 x 105 cells per well in 6-well plates, respectively.
For SR conditions, cells were adjusted to SR medium for 48 hours before growth determination.
Cells were harvested every 72 hours on days 0, 3, 6, and 9. Cell viability was measured using trypan
blue exclusion dye. Results presented are mean ± SE. n=3x3. *p<0.05, **p<0.005, ***p<0.0005.
Cells were then lysed to determine PCNA levels via western blot analysis to confirm cell growth
results. β-actin protein level was used as a loading control.
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Figure 3.2. Colony Formation and Migration of AS and AI PCa Cells.
A-C) AS and AI LNCaP, MDA PCa2b, and VCaP cells were plated in 6-well plates at 3 x 103, 1 x
104, and 1 x 104 cells per well, respectively. LNCaP cells were maintained in regular RPMI 1640
medium for 9 days, with a fresh change of medium every 3 days. MDA PCa2b and VCaP cell lines
were maintained in HPC1 and DMEM, respectively, for 14 days, with a fresh change of medium
every 3 days. Cells were stained with 0.02% crystal violet containing 50% methanol. The stained
cells were then photographed at 40x magnification for counting. Results presented are mean ± SE.
n=3x2. *p<0.05, **p<0.005, ***p<0.0005.
D-F) AS and AI LNCaP, MDA PCa2b, and VCaP cells were plated in the upper chamber of the
transwell inserts at 5 x 104, 6 x 104, and 6 x 104 cells, respectively, in regular medium. Cells were
allowed to migrate for 24 hours, at which time cells in the upper chamber were removed via a
cotton swab, and the cells that had migrated through the insert were stained with 0.02% crystal
violet containing 50% methanol. Images were taken at 400x magnification. Results presented are
mean ± SE. n=2x3. *p<0.05, **p<0.005, ***p<0.0005.
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Figure 3.3. ROS Levels and Signaling Pathways in AS and AI Cells.
A-C) DCF-DA Analysis. AS and AI LNCaP (A), MDA PCa2b (B), and VCaP (C) cells were plated
at 1 x 105, 5 x 105, and 3 x 105 cells per T25 flask and grown for 72 hours until flasks were about
60%-70% confluent. Cells were trypsinized and stained with 20 μM DCF-DA for 30 minutes in the
dark and subjected to flow cytometry analysis. The data shown is a representative of three sets of
experiments, and similar results were obtained. n=3.
D) Immunoblot analysis of the signaling pathways in LNCaP, MDA PCa2b, and VCaP PCa cells.
LNCaP, MDA PCa2b, and VCaP cells were plated in T75 flasks at 1.5 x 104, 4 x 105, and 4 x 105
cells per flask in the regular steroid-containing medium for 72 hours. Cells were harvested via
scrapping and lysed. Total cell lysates were analyzed for Shc, AR, cPSA, PAcP, FOXM1,
CDC25B, Cyclin B1, Snail, Nrf2, and HO-1. Lysates were also analyzed for total and
phosphorylated ErbB-2, AKT, ERK, mTOR, and PYK2, as well as total Rac1 and GTP-Rac1. βactin protein level was used as a loading control. The data shown is a representative of three sets
of independent experiments, and similar results were obtained. n=3.
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Figure 3.4. Effects of Altered ROS Levels on AS PCa Growth and Migration.
A-C) Trypan Blue Exclusion Assay. LNCaP-AS (A), MDA PCa2b-AS (B), and VCaP-AS (C) cells
were plated at 2 x 104, 2 x 104, and 2 x 104 cells per well, respectively, for 72 hours. Cells were
treated with 0-20 μM H2O2 or 10 mM NAC for 72 hours before cells were harvested and counted
via trypan blue exclusion dye. Results presented are mean ± SE. n=3x3. *p<0.05, **p<0.005,
***p<0.0005.
D-E) Boyden Chamber Transwell Assay. LNCaP-AS (D), MDA PCa2b-AS (E), and VCaP-AS (F)
cells were plated at 5 x 104, 6 x 104, and 6 x 104 cells, respectively, in the upper chamber of a
transwell insert for 24 hours with 10 μM H2O2 and/or 10 mM NAC treatments. Cells in the upper
chamber were removed via a cotton swab, and the cells that had migrated through the insert were
stained with 0.02% crystal violet containing 50% methanol. Images were taken at 400x
magnification. Results presented are mean ± SE. n=2x3. *p<0.05, **p<0.005, ***p<0.0005.
G) LNCaP-AS cells were plated at 5x 104 cells per well in 12-well plates for 48 hours. Cells were
treated with 10 μM H2O2 and/or 10 mM NAC for 24 hours. H2O2 levels were labeled with Peroxy
Orange-1 fluorescence indicator for 1 hour before the reaction was quenched. DAPI was utilized
to stain the nucleus. Fluorescence was visualized via a confocal microscope. Color adjustment was
applied equally in all images shown. The data shown is a representative of three sets of independent
experiments upon which 20 cells were quantified, and similar results were obtained. n=3. *p<0.05,
**p<0.005.
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Figure 3.5. Cell Proliferation and Cellular Oxidative Environment in LNCaP-AS and
LNCaP-AI Cells and p66Shc Subclones.
LNCaP-AI (A) and V1 and p66Shc subclone (B) cells were plated at 2 x 104 cells per well in 6well plates for 48 hours. Cells were transfected with vector or p66Shc shRNA, then grown for an
additional 72 hours before cells were harvested via trypsin. Cell viability was measured using
trypan blue exclusion dye. Results presented are mean ± SE. n=3x3. *p<0.05, **p<0.005,
***p<0.0005. Cells were then lysed to determine Shc protein levels via western blot analysis to
confirm proper transfection. β-actin protein level was used as a loading control.
LNCaP-AI cells (C) and p66Shc subclones (D) with vector alone transfected V1 cells were plated
at 5 x 104 cells per well in 12-well plates for 48 hours. Cells were transfected with vector or p66Shc
shRNA, then grown for an additional 24 hours before cells were harvested via trypsin. Cells were
trypsinized and stained with 20 μM DCF-DA for 30 minutes in the dark and subjected to flow
cytometry analysis. The data shown is a representative of three sets of experiments, and similar
results were obtained. n=3. *p<0.05.
E-F) LNCaP-AI cells and p66Shc subclones with vector alone transfected V1 cells were plated at
5 x 104 cells per well in 12-well plates for 48 hours. Cells were transfected with vector or p66Shc
shRNA, then grown for an additional 24 hours before cells were harvested via trypsin. H2O2 was
labeled with Peroxy Orange-1 fluorescence indicator for 1 hour before the reaction was quenched
(E). Mitochondrial O2- levels were labeled with MitoSOX fluorescence indicator for 1 hour (F).
DAPI was utilized to stain the nucleus. Fluorescence was visualized via a confocal microscope.
Color adjustment was applied equally in all images shown. The data shown is a representative of
three sets of independent experiments, and similar results were obtained. Twenty cells were imaged
for each treatment in each independent experiment. n=3. *p<0.05, **p<0.005.
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Figure 3.6. Phosphoprotein Microarray Analysis of LNCaP Cell Progression Model and
p66Shc Subclones.
Total cell lysates of LNCaP-AS and LNCaP-AI cells or V1 control cells and equally mixed
population of stable S31, S32, and S36 p66Shc subclones were analyzed via KAM-900P protein
microarray by Kinexus. Results are presented in which red represents an increase and green a
decrease in phosphoprotein or protein levels comparing the LNCaP-AI cells or p66Shc subclones
to AS LNCaP or V1 cells, respectively.
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Figure 3.7. ROS and p66Shc Effect on Signaling Profile in LNCaP-AS Cells and p66Shc
Subclones.
Immunoblot analysis of (A) LNCaP-AS cells upon treatment with 10 μM H2O2 and/or 10 mM NAC
and LNCaP-AI cells (B) and p66Shc subclones upon knockdown of p66Shc. Cells were plated in
T75 flasks at 1.5 x 104 cells per flask in regular steroid-containing medium for 72 hours, before
being treated with 0-20 μM H2O2 and/or 10 mM NAC for 72 hours. Cells were harvested via
scrapping and lysed. A) Total cell lysates were analyzed for Shc, AR, cPSA, FOXO3a, and
FOXM1. Lysates were also analyzed for total and phosphorylated ErbB-2, AKT, ERK, mTOR, and
PYK2, as well as total and GTP-Rac1. B) Total cell lysates of p66Shc subclone cells and p66Shc
subclones transfected with p66Shc shRNA were analyzed for Shc and FOXM1. Lysates were also
analyzed for total and phosphorylated ErbB-2, AKT, ERK, mTOR, and PYK2. β-actin protein level
was used as a loading control. The data shown is a representative of three sets of independent
experiments, and similar results were obtained. n=3.
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Figure 3.8. In vivo Models of LNCaP Cell Progression Model and p66Shc Subclones.
A) Western blot analysis of Shc in LNCaP-AS, LNCaP-AI, V1, and p66Shc subclone cells. β-actin
protein level was used as a loading control.
Orthotopic injection of 2 x 106 AS or AI LNCaP cells into male athymic nude mouse prostates or
subcutaneous injection of 1 x 106 AS or AI LNCaP cells or V1 and p66Shc subclones into male
(regular conditions) or female (castrated conditions) mice dorsal surface. Tumors were allowed to
grow for 8 weeks before animals were sacrificed. n=10 to 20 mice per group. B) Mice with
metastasis 7-8 weeks post orthotopic injection was recorded. C) Imaging of LNCaP-AI-LUC
tumors in mice 3 weeks post-implantation. D) Photograph of p66Shc subclone tumor metastasis to
the GI tract (left) and pancreas (right). E) Location of metastasis recorded in mice implanted with
LNCaP-AI tumors.
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Figure 3.9. Dynamic Balance of ROS in PCa Progression.
A) Diagram of the balance of ROS in PCa cells. PCa cells are documented to have higher levels of
ROS than benign tissue. AS PCa cells have moderate levels of ROS, which can be reduced by NAC
treatment or antioxidant enzymes to reduce tumorigenicity. Increased ROS in AS PCa cells via
H2O2 or pro-oxidants can promote PCa tumorigenicity and thus, more aggressive cancer and obtain
the CR phenotype.
B) p66Shc is an authentic oxidase which has been demonstrated to produce ROS, particularly
superoxide. Increased cellular ROS oxidizes cellular prostatic acid phosphatase (cPAcP),
preventing it from dephosphorylating ErbB-2. Phosphorylated ErbB-2 then activates downstream
targets PI3K/AKT/mTOR, ERK, PYK2, and Rac1, all of which contribute to PCa cell proliferation
and migration.
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Chapter 4
Novel CIL-102 Derivatives as Potential Therapeutic Agents for
Docetaxel-Resistant Prostate Cancer
This chapter is derived from:
Miller DR, Tzeng CC, Farmer T, Keller ET, Caplan S, Chen YS, Chen YL, Lin MF (2018) Novel
CIL-102 Derivatives as Potential Therapeutic Agents for Docetaxel-Resistant Prostate Cancer.
Cancer Letters 436: 96-108.
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4.1 Synopsis
The standard-of-care treatment for metastatic PCa is ADT. Nevertheless, most tumors eventually
relapse and develop into lethal CR PCa. Docetaxel is an FDA-approved agent for the treatment of
CR PCa; however, the tumor often quickly develops resistance to this drug. Thus, there is an
immediate need for novel therapies to treat docetaxel-resistant PCa. In this study, we modified the
structure of CIL-102 and investigated the efficacy of the derivatives against CR PCa and docetaxelresistant PCa. These novel CIL-102 derivatives inhibit CR PCa tumorigenicity, including
proliferation, migration and colony formation, and importantly, selectively inhibit CR PCa cell
proliferation over non-cancerous prostate epithelia. Computational modeling indicated the
derivatives bind to β-tubulin and immunocytochemistry revealed the depolymerization of
microtubules upon treatment. Western blot analyses reveal that pro-apoptotic and anti-oxidant
pathways are activated, and MitoSOX and DCF-DA analyses confirmed increased reactive oxygen
species (ROS) production upon treatments. Furthermore, CIL-102 derivatives effectively reduce
the proliferation of docetaxel-resistant CR PCa cell lines. Our data indicate the potential of these
compounds as promising therapeutic agents for CR PCa as well as docetaxel-resistant CR PCa.
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4.2 Background and Rationale
Docetaxel is a common therapeutic agent for many types of advanced cancers, including CR PCa
[167]. This FDA-approved drug stabilizes microtubule polymerization, leading to mitotic arrest,
apoptosis, inhibition of cellular trafficking, and cessation of AR signaling [168,169]. However,
taxanes have low selectivity, which results in high toxicity and a low therapeutic index. Further,
cancer cells can develop resistance to taxanes via Multi-drug resistance 1 (MDR1) expression,
mutations in tubulin, or differential expression of tubulin isotypes, rendering the drug useless
[167,170]. Treatment of CR PCa patients with docetaxel can prolong survival by about 3 months.
Cabazitaxel is a third-generation taxane utilized in CR PCa treatment intended to overcome
docetaxel resistance; however, increased MDR1 protein levels can also induce efflux of this anticancer agent from the cell. Thus, taxanes lose effectiveness. Similar to docetaxel, cabazitaxel is
also quite toxic to patients and can result in many severe side effects as well [171,172]. Upon
development of docetaxel resistance in CR PCA, there are very few remaining therapeutic options
that have minimal toxicity to patients. Thus, there is an immediate need to develop novel therapies
for docetaxel-resistant CR PCA.

One potential method of treating docetaxel-resistant PCa or CR PCa is with the compound CIL102, a microtubule-binding agent that interacts with the colchicine-binding site of tubulin and
destabilizes the microtubules; thus, inhibiting cell division [146,173]. CIL-102 has anticancer
effects in various cancer types, including multidrug-resistant cancer cell lines, via cell cycle arrest
in the G2/M phase [174-176]. In addition, CIL-102 has cytotoxic effects and induces ROS
generation, resulting in apoptosis via the p53/p21 apoptotic pathway, as well as cell cycle arrest
upon increased protein levels of Growth Arrest and DNA Damage-Inducible 45 (GADD45)
[146,175-177]. Further, CIL-102 treatment reduces mRNA expression of matrix metalloprotease2/-9 (MMP-2/MMP-9) proteins commonly involved in tumor progression, invasion, and metastasis

66
[178]. However, the binding of a drug at the colchicine-binding site is also equally toxic to
noncancerous cells [179], which has led to the development of new generations of CIL-102
derivatives to improve its selectivity and stability. While the second generation of CIL-102
derivative

(E)-1-{4-[(3-chloro-7-methoxyfuro[2,3-b]quinolin-4-yl)(methyl)amino]phenyl}

ethanone O-(2-aminoethyl) oxime (compound 1) has improved the selectivity, it is still marginal
[180]. Synthesis of the third generation derivatives may lead to a further improved selectivity of
these compounds.

Based on the structure of compound 1 [180], we synthesized the third generation of CIL-102
derivatives and analyzed these compounds for their efficacy against the proliferation of AI LNCaP
C-81 and VCaP-AI cells which exhibit the CR PCA phenotype [14,132,133,154]. We also
examined the efficacy of these compounds on neuroendocrine (NE)-like PCa cells, another lethal
form of PCa that develop in part upon prolonged ADT [181-185]. In addition, the effects of these
derivatives on noncancerous prostate epithelial RWPE-1 cell proliferation was analyzed to
determine the selectivity of these novel compounds, a property of reducing adverse effect in
treatments. The CIL-102 derivatives were also investigated for their ability to inhibit
predispositions of LNCaP C-81 tumorigenicity, including migration, clonogenic growth, and
anchorage-independent growths. Furthermore, cell cycle analysis, tubulin polymerization and ROS
production were all analyzed upon CIL-102 derivative treatment to determine the compounds’
mechanism of action. Importantly, our data showed that these novel derivative compounds
consistently inhibited the growth of several docetaxel-resistant PCa cell lines, including PC-3,
LNCaP C-81, and VCaP-AI cells.

4.3 Results
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4.3.1 CIL-102 Derivatives Selectively Reduce CR PCA Cell Viability and Proliferation
Initially, our collaborators at Kaohsiung Medical University in Taiwan synthesized nineteen third
generation CIL-102 derivatives based on the structure of compound 1 (Fig. 4.1) [185]. We screened
them via MTT assay for their ability to reduce CR PCa cell viability, compared with compound 1
as the positive control. LNCaP C-81 cells that exhibit the CR PCa phenotype [14,132,133,154]
were used as our model system and were treated with 1 μM each of the CIL-102 derivatives for 72
hours. Compounds 1, 6, 7, 8, 9, 10, 15, 22, and 23 effectively reduced LNCaP C-81 cell viability
by 50% or more (Fig. 4.2A). To investigate further the potential of translational application, we
determined the effectiveness of those selected compounds on VCaP-AI cells, another AR-positive
CR PCA cell line [14], and also the selectivity of PCa over RWPE-1 non-cancerous prostate
epithelia via MTT assay (Fig. 4.2B). In general, these compounds were not as effective at inhibiting
VCaP-AI cell viability compared to LNCaP C-81 cells. While several compounds had a similar
inhibitory effect on cell viability of VCaP-AI and RWPE-1 cells, compounds 10, 22, and 23 showed
a significant reduction of inhibiting cell viability of RWPE-1 cells compared to both LNCaP C-81
and VCaP-AI PCa cells. Based on the enhanced selectivity with retained toxicity compared to the
other CIL-102 derivatives, compounds 22 and 23 were chosen for further analysis.
We further evaluated compounds 22 and 23 for their dosage effects on cell viability via trypan blue
exclusion assay, comparing to the second generation compound 1 and another third generation
compound 6. LNCaP C-81 cells were used as a model system and treated with increasing
concentrations of the four CIL-102 derivatives for 3 days in SR conditions to mimic the
environment under ADT. The 50% proliferation inhibition concentration (IC50) of compounds 1,
6, 22, and 23 were calculated to be 235 nM, 290 nM, 672 nM, and 680 nM, respectively (Fig. 4.3A
and 5.4B). Western blot analysis on cyclin B1 confirmed the decrease in cell proliferation with
increasing concentration of 22 and 23 (Fig. 4.3C).
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We further determined the effects of 1 µM CIL-102 derivative treatment on cell viability under SR
conditions utilizing trypan blue exclusion assay as 1 µM is a clinically achievable compound
concentration. All four compounds led to a significant reduction in cell proliferation of LNCaP C81 cells, resulting in about a 90% decrease in cell growth (Fig. 4.3D). There was no significant
difference in the inhibition of cell proliferation between compound 1 and 6 or 22; however, there
was a significant difference between 1 and 23. This trend was also seen in VCaP-AI cells, which
had about an 80-85% reduction in cell growth upon treatment with the four CIL-102 derivatives
(Fig. 4.3E). There was no significant difference between 1 and 6, 22, or 23.
We examined if these compounds could also effectively reduce the proliferation of NE-like PCa
cells because the results of clinical studies show the increase of NE-like PCa cell population upon
prolonged ADT [186,189,190]. As shown in Figure 5.3F, NE 1.3 and NE 1.8 cells were also
sensitive to the CIL-102 compounds. NE 1.3 cell proliferation was reduced by 90% for all three
compounds at a 1 μM concentration, while the proliferation of NE 1.8 cells was reduced by 1, 22,
and 23 with over 85%, 80%, and 75%, respectively (Fig. 4.3F). While PC-3 cells were more
resistant to 1 μM CIL-102 derivative treatment with only 50-60% growth inhibition at this
concentration; 5 μM and 10 μM treatments led to about 80% growth inhibition for all three
compounds (Fig. 4.3G). IC50 values of 1, 22, and 23 in PC-3 cells was 1.59 μM, 1.85 μM, and 2.23
μM, respectively.
Lastly, for the potential of translational application, the selectivity of the CIL-102 derivatives was
determined by analyzing the efficacy of growth suppression in immortalized, non-cancerous
prostate epithelial RWPE-1 cells. While all three compounds resulted in some degrees of reduction
of cell proliferation, there was no significant inhibition of RWPE-1 cell proliferation upon
treatment with 22 or 23 at about 20% and 30% cell growth inhibition, respectively. However,
compound 1 treatment resulted in a significant 55% decrease in RWPE-1 cell growth (Fig. 4.3H).
Further, there was a significant difference in cell growth inhibition between 1 and 22, showing that
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compound 22 has increased selectivity as compared to parent compound 1. Nevertheless, due to a
lower IC50 value of compound 1 than its derivatives on PCa cells, we further analyzed the
selectivity of compound 1 in RWPE-1 cells. Upon reduction of the concentration of compound 1
to 500 nM, there was still a 40% decrease in RWPE-1 cell proliferation (data not shown). Thus, the
data clearly demonstrated the improved selectivity of compounds 22 and 23 from second generation
compound 1.

5.3.2 CIL-102 Derivatives Reduced LNCaP C-81 Cell Tumorigenicity
We analyzed the effects of the CIL-102 derivatives on LNCaP C-81 cell tumorigenicity, including
clonogenic and soft agar assays, and also Boyden chamber transwell migratory activity. For the
transwell migration analysis, LNCaP C-81 cells were treated with 1 μM of compound 1, 22, and
23 for 24 hours. Fig. 4.4A showed that compound 1 greatly reduced migration with 70% inhibition,
followed by 22 at 60%, and 23 at 55% reduction. Nevertheless, there was no significant difference
in inhibition of migration between 1 and 22 or 23.
For the clonogenic assay, LNCaP C-81 cells were treated with compound 1, 22, and 23 at 0.5 μM.
1-treated cells had a 99% reduction in colony formation, while 22 and 23 inhibited colony
formation by 95% and 90%, respectively (Fig. 4.4B). There was no significant difference between
1 and 22 treatments, while there was a significant difference between 1 and 23.
Lastly, the soft agar assay was utilized to determine the effects of the CIL-102 derivatives on
anchorage-independent colony formation. LNCaP C-81 cells were treated with 1 μM of compound
1, 22, and 23. The greatest reduction of colony formation in colony number and size occurred in
22-treated cells at about 55%, followed by 1 at 50% reduction, and 23 at 45% (Fig. 4.4C). There
was no significant difference between 1, and 22 or 23. Thus, the third-generation derivatives 22
and 23 have the ability to suppress the tumorigenicity of CR PCA cells.
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4.3.3 Effects of CIL-102 Derivatives on LNCaP C-81 Cell Cycle Progression
The CIL-102 parental compound inhibits microtubule formation and promotes cell death [146, 186191]; thus, we analyzed the effects of its derivatives on cell cycle and apoptosis. LNCaP C-81 cells
were treated with 1 μM of the CIL-102 derivatives for 72 hours. Cells were stained with Telford
reagent and analyzed for cell cycle and apoptosis via flow cytometry. Compound 1-treated cells
had a 3-fold increase in the G2/M phase, while 22 and 23 resulted in an approximately 50% increase
in G2/M phase as well as the S phase (Fig. 4.5A). Further, compound 1 treatment led to a 10-fold
increase in apoptosis, while there was an increase in 22- and 23-treated cells with a lower efficacy
of 5-fold and 3-fold increase, respectively. This suggests that there are different mechanisms by
which compounds 22 and 23 suppress growth compared to compound 1.

4.3.4 CIL-102 Derivatives Bind to Tubulin and Reduce Microtubule Polymerization
To assess the ability of the CIL-102 derivatives to inhibit the microtubule formation, we visualized
α-tubulin, which together with β-tubulin comprises microtubules, via confocal microscopy (Fig.
4.5B). In control cells, α-tubulin displayed consistent localization to typical microtubule structures
(see insets for Control). Treatment with 0.25 μM or 0.50 μM of compounds 1, 22, and 23 all led to
a dramatic reduction in intact microtubule structures, and reduced fluorescence signals that could
be attributed either to cytoplasmic scattering and/or some tubulin degradation. A higher
concentration of 1 μM resulted in the absence of intact microtubules in treated cells.
Computational modeling was utilized to illustrate the CIL-102 compounds binding site at the
tubulin subunits resulting in microtubule depolymerization. We began by analyzing CIL-102
binding to β-tubulin via 1-Click Docking by mcule. Specific residues reported by Gireesh et al.
[146] were first analyzed for the optimal score. Nevertheless, our own computational analysis
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revealed the optimal binding of CIL-102 at an alternative location on the β-tubulin subunit.
Utilizing the residues provided from our analysis, it was determined that docking at the Asn197
residue of β-tubulin resulted in binding scores of 1 at -9.0, followed by CIL-102 at -8.7, then 22
and 23 at -7.7 (Fig. 4.5C).

4.3.5 CIL-102 Derivative Treatment Increases Antioxidant Enzymes and Apoptotic
Signaling Pathways
To determine the effects of the CIL-102 derivatives on molecular signaling in LNCaP C-81 (Figure
4.6A) and RWPE-1 (Figure 4.6B), western blot analysis was conducted, and the band intensities
on the blots were quantified via ImageJ. Upon 1 μM treatment with compound 1, 22, and 23, there
was only a slight reduction in AR protein levels in LNCaP C-81 cells. Interestingly, there was a
reduction in secreted PSA upon treatment with compounds 22 and 23 but increased upon treatment
with 1, while cellular PSA levels were decreased upon treatment with all three compounds. Both
forms of PSA are indicative of AR activity; however, secreted PSA is the molecule that is utilized
as a biomarker for PCa diagnosis or progression. Phospho-ERK1/2 levels were increased upon 22
and 23 treatment, while phospho-ERK was reduced with treatment of compound 1 and total
ERK1/2 protein levels were unchanged by the CIL-102 treatments. Phosphorylated AKT levels
were unchanged by the treatments, and total AKT protein was increased by 22 treatment, however
downstream target Survivin levels were dramatically increased by 1 treatment. The inconsistent
trends seen between compounds 1, 22, and 23 suggest that the third generation CIL-102 derivatives
have a different mechanism of action compared to the second generation compound 1. Western blot
analysis also revealed that there were increased protein levels of antioxidant enzymes Nrf2 and
downstream HO-1 upon 22 and 23 treatments. The elevation of these antioxidant proteins suggests
that the CIL-102 derivatives can promote excess ROS generation and, therefore, elicit an
antioxidant response in order to compensate for these potentially toxic ROS levels. As for apoptotic
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pathways, anti-apoptotic BclXL protein levels remained unchanged in 1-treated cells, while 22 and
23 treatments led to a slight increase in protein levels. Bax was increased upon 1 treatment, but not
22 and 23 treatments. Tumor suppressor p53 was elevated upon all three treatments as well, most
prominently upon treatment with compounds 22 and 23. Cleaved Caspase 3 protein levels were
greatly increased upon 1 treatment and was detected at low levels in 22-treated cells as well.
Cleaved PARP was increased significantly in 1-treated cells and also detected upon 22 and 23
treatments. Thus, CIL-102 derivative treatments promote an increase in antioxidant proteins as well
as pro-apoptotic proteins in treated PCa cells.
We analyzed CIL compounds for similar effects on redox and/or apoptotic proteins in RWPE-1
non-cancerous cells as observed in PCa LNCaP C-81 cells. Figure 3H showed that RWPE-1 cells
are resistant to 22 and 23 treatment growth inhibition. Western blot analyses revealed that RWPE1 cells were also resistant to CIL-102 derivative-mediated alteration in antioxidant enzymes as well
as the induction of apoptosis upon treatment with the CIL-102 derivatives (Figures 4.6B). CIL-102
derivatives did not significantly alter HO-1 protein levels. Interestingly, Bax pro-apoptotic protein
levels were increased by 100% when RWPE-1 cells were treated with 1, but not 22 or 23 treatment.
BclXL anti-apoptotic protein levels increased upon all three treatments, as did total Caspase 3 levels.
We were unable to detect any Cleaved Caspase 3 or total or cleaved PARP in RWPE-1 cells with
any of the three treatments. Our data thus revealed that RWPE-1 cells are insensitive to the CIL102 derivatives treatments, particularly 22 and 23, as indicated by no detected apoptotic markers
in their cell signaling profile. Importantly, the increase in anti-apoptotic BclXL protein levels upon
treatment of RWPE-1 cells with the third-generation of CIL-102 derivatives agrees with the results
in Figure 5.3H which compounds 22 and 23 exhibit increased selectivity toward non-cancerous
prostate epithelial cells as compared to compound 1.

4.3.6 CIL-102 Derivatives Increase ROS Generation in LNCaP C-81 PCa Cells
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To determine if elevated Nrf2 and HO-1 levels were due to increases in ROS, we analyzed
mitochondrial superoxide levels via MitoSOX staining. Briefly, after treatment of LNCaP C-81
cells with 1 μM of 1, 22, or 23 for 24 hours, cells were stained via MitoSOX. Comparing control
cells to derivative-treated cells, there was a significant increase in mitochondrial superoxide levels.
Semi-quantification showed that there was about a 3-fold increase in superoxide detected in 1-, 22, or 23-treated cells over control cells (Fig. 4.7A). Similarly, DCF-DA analysis showed that there
is a significant increase in total ROS levels (Fig. 4.7B). CIL-102 derivative treatments resulted in
a significant increase in ROS levels by about 30% with 22 and 23 treatments and 60% with 1
treatment (Fig. 4.7B). Unexpectedly, RWPE-1 cells treated with the CIL-102 derivatives had
reduced MitoSOX staining compared to control cells (Fig. 4.7C). Compound 1 treatment resulted
in the lowest reduction of MitoSOX fluorescence at 40%, while compounds 22 and 23 reduced
MitoSOX staining by about 60%.

4.3.7 CIL-102 Derivatives Effectively Inhibit Docetaxel-Resistant PCa Cell Proliferation
To investigate if the CIL-102 derivatives could potentially serve as alternative therapeutics to treat
docetaxel-resistant PCa cells, trypan blue dye exclusion assay was conducted on docetaxelsensitive and docetaxel-resistant PC-3, LNCaP C-81 and VCaP-AI cell lines (Fig. 4.8). Upon
docetaxel treatment (10 nM), the growth of docetaxel-sensitive PC-3 cells, but not the docetaxelresistant PC-3 cells, was inhibited by 75% (Fig. 4.8A). In docetaxel-sensitive PC-3 cells, treatment
with 1 µM each of the CIL-102 derivatives resulted in about a 60% reduction in cell growth with
compound 1 and 22, and 50% reduction by 23 treatment (Fig. 4.8A). In comparison, docetaxelresistant PC-3 cells were just as susceptible to CIL-102 derivative treatments with about 50-60%
growth inhibition by all three compounds. Thus, there is no significant difference between growth
inhibition by CIL-102 derivative on docetaxel-sensitive and docetaxel-resistant PC-3 cells (Fig.
4.8A).
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A similar trend was seen in the docetaxel-sensitive and docetaxel-resistant LNCaP C-81 cells (Fig.
4.8B) and VCaP-AI cells (Fig. 4.8C). Treatment with docetaxel (3 nM) reduced docetaxel-sensitive
LNCaP C-81 cell growth by over 65%, while the docetaxel-resistant cells had less than 15% growth
inhibition. Comparing the CIL-102 derivative treatments, there was 70-80% growth inhibition upon
1 μM compound 1, 22, and 23 treatments in both docetaxel-sensitive and docetaxel-resistant
LNCaP C-81 cells, with no significant difference in growth inhibition between the two sub-lines.
Similarly, treatment of docetaxel-sensitive VCaP-AI cells with docetaxel (2 nM) led to over 65%
reduction in cell growth, while docetaxel-resistant cells experienced less than 20% reduction in cell
proliferation. Upon treatment of these cells with compounds 1, 22, or 23, both docetaxel-sensitive
and docetaxel-resistant VCaP-AI cells resulted in about a 70-80% reduction in cell proliferation.
Again, there was no significant difference between the growth inhibition in docetaxel-sensitive and
docetaxel-resistant cells.

4.4 Discussion and Conclusions
CR PCa, especially docetaxel-resistant CR PCa, is a lethal disease to which patients succumb
shortly upon development; thus novel effective treatment options are desperately needed. One
potential therapeutic option is the utilization of the compound CIL-102 to target microtubule
polymerization because cancerous cells divide at more rapid rates than noncancerous cells. Due to
the toxicity of the CIL-102 parental compound, several generations of this molecule have been
synthesized to increase the selectivity for over-coming the adverse effects in patients. In this report,
we investigated the potential of the third generation of CIL-102 derivatives, including compounds
22 and 23, against their parent compound 1 for efficacy and selectivity to treat CR PCa and
docetaxel-resistant CR PCa cells, utilizing multiple CR PCa cell lines including both AR-positive
and -negative cells. Our data clearly show that these compounds inhibit CR PCa cell growth as well
as their docetaxel-resistant subline cells, but not non-cancerous prostate epithelia.
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The initial screen included nineteen third generation derivatives of CIL-102 in AI LNCaP C-81 and
VCaP cells, plus non-cancerous prostate RWPE-1 cells via MTT assay (Fig. 5.2). Because
compounds 22 and 23 had greater selectivity with less toxicity to RWPE-1 cells, these two
molecules were further analyzed for their ability to inhibit PCa cell growth via trypan blue dye
exclusion assay as compared to parent compound 1 and an additional control of compound 6
following a dosage reaction. Despite the fact that compound 1 and 6 had much lower IC50 values
than that of 22 and 23 (Fig. 4.3A and 4.3B), all IC50 values were below 1 μM, a clinically
achievable concentration. Next, 1 μM treatments of 1, 6, 22, and 23 in AI LNCaP C-81 and VCaPAI PCa cells showed that all four compounds lead to about 80-90% reduction in cell proliferation
(Fig. 4.3D and 4.3E). Thus, compounds 22 and 23 can effectively reduce AR-positive AI PCa cell
proliferation, the dominant CR PCa cell population.
Clinical studies show prolonged ADT increases NE-like cell population by secretion of growth
stimuli to promote CR PCa progression under ADT [184]. Fig. 4.3F clearly shows that both NE1.3 and NE-1.8 cells are also sensitive to 1 μM CIL-102 derivative treatment and have a similar
80-90% reduction in their growth. PC-3 cells are proposed to be an NE-like PCa cell line [128].
While PC-3 cells are less sensitive to 1 μM treatments with about 60% inhibition; 5 μM treatment
reduced cell proliferation by 80% (Fig. 4.3G), which is still within a clinically achievable range.
We further analyzed 1 μM CIL-102 derivative effects on noncancerous prostate epithelial RWPE1 cells, and importantly, results of Figures 4.2B and 4.3H clearly revealed that compounds 22 and
23 did not significantly reduce the proliferation of RWPE-1 cells, and compound 22 is significantly
less growth inhibition against RWPE-1 cells compared to 1 (Fig. 4.3H) [180]. Treatment of all three
CIL-102 derivatives, 1, 22 and 23, led to a significant reduction of AI LNCaP C-81cell migration,
2D plasticware colony formation and 3D soft agar colony formation (Fig. 4.4).
Cell cycle analysis demonstrated that 1 treatment results in a significant increase in cell cycle arrest
in G2/M phase as well as a substantial increase in apoptosis, while 22 and 23 treatments led to
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moderate increases in both S and G2/M phases as well as apoptosis (Fig. 4.5A). The increase in
G2/M phase cell cycle arrest also suggests that the CIL-102 derivatives are interfering with tubulin
polymerization. Visualization using confocal microscopy revealed that tubulin structures were
depleted upon treatment with the CIL-102 derivatives at concentrations of both 250 nM and 500
nM as compared to the control (Fig. 4.5B), which was also seen in Gireesh et al. [146]. Thus, our
data in conjunction with Gireesh et al. [146] support the hypothesis that binding at the colchicinebinding site by CIL-102 and its derivatives, as well as other colchicine binding agents [173], results
in destabilization of microtubules in contrast to the stabilization seen with docetaxel treatment.
Computational modeling was performed and analyzed on several interaction sites on the tubulin
subunit, based on both our own results as well as Gireesh et al. [146]. The results of our modeling
show that the binding score for compound 1 is on par with CIL-102, while 22 and 23 have slightly
reduced binding scores compared to 1 (Fig. 4.5C), potentially suggesting an alternative mechanism
of action. The docking model based on Gireesh at al. shows a different landscape of CIL-102
derivative binding. The binding scores of CIL-102 and 1 are once again similar; however, the
binding scores drop dramatically with 22 and 23, with 23 being higher than 22. Nevertheless,
compounds 22 and 23 have very similar IC50 values with 22 having a similar efficacy as 23 on
biological effects. Therefore, we propose the docking model in Figure 5C is a more appropriate
model of CIL-102 derivative binding to β-tubulin.
Western blot analysis revealed that there was an increase in antioxidant enzymes as well as those
of pro-apoptotic pathways in cancerous LNCaP C-81 cells but not normal prostate epithelial
RWPE-1 cells (Fig. 4.6). Further, activation of the ERK pathway was seen upon treatment of
LNCaP C-81 cells with 22 and 23, while there was inhibition of these pathways with compound 1,
suggesting different mechanisms of action between the second and third generation of compounds
which should further be explored. There was also an elevation of p53 protein level upon treatment
with the three compounds, suggesting its potential role in CIL-102 derivative-mediated cell death.
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LNCaP C-81 and VCaP-AI cells have wildtype 53 and heterozygous p53 mutant, respectively,
while PC-3 cells are p53-null [199]. Thus, this may be a mechanism of higher IC50 values for the
CIL-102 derivatives in PC-3 cells compared to LNCaP C-81 and VCaP-AI cells (Fig. 4.3G).
Interestingly, prolonged ERK activation has the ability to be pro-apoptotic via increased
stabilization of p53 and growth arrest [186,187]; thus, strengthening the case for compounds 22
and 23 to promote apoptosis through p53 as well as Caspase 3 and PARP cleavage. MitoSOX
indicator, as well as DCF-DA analysis, demonstrated the increase in ROS levels upon treatment
with the CIL-102 derivatives in LNCaP C-81 cells, while MitoSOX levels were reduced in noncancerous RWPE-1 cells (Fig. 4.7). Thus, an excessive increase of ROS production may be one
mechanism by which the CIL-102 derivatives promote cell death in PCa cells. Our working
hypothesis is demonstrated in Figure 5.9. Briefly, inhibition of microtubules via CIL-102 derivative
treatment leads to the induction of cancer cell death through cell cycle arrest via p53 and
microtubule depolyermization. A potential mechanism for the depolymerization is through
oxidation of microtubules themselves, which has been demonstrated in several other studies
[188,189]. This could suggest that these CIL-102 derivatives have unknown targets and the cellular
cytotoxic response to these molecules leads to increased mitochondrial ROS production and
subsequent oxidation of microtubules. Further analysis is required to confirm microtubule
oxidation upon CIL-102 derivative treatment.
In summary, our data reveal that the third generation of CIL-102 compounds, especially 22,
demonstrate the selectivity for CR PCa cells over the immortalized non-cancerous prostate
epithelial RWPE-1 cells. Importantly, these compounds are also effective against several docetaxelresistant PCa (Fig. 4.8). In docetaxel-resistant PC-3 cells, MDR1 was marginally upregulated, thus
it was determined to not be the major factor in the acquisition of the resistant phenotype [190].
Currently, the mechanism by which PCa cells are resistant to docetaxel but not the CIL-102
derivatives is still unknown, thus further studies are warranted. Taken together, the data is the first
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step to show that CIL-102 derivatives 22 and 23 can be utilized as selective inhibitors for both CR
PCa and docetaxel-resistant CR PCa plus NE-like PCa cells. Further analysis is required to
determine the effects of these compounds in vivo.
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4.5 Figures

Figure 4.1. Structure of N-Alkyl 4-Anilinofuro[2,3-b]quinolone (CIL-102) compounds.
Structure of CIL-102 (parent compound), 1 (second generation compound), 6, 22, and 23 (third
generation compounds).
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Figure 4.2. Effects of CIL-102 Derivatives on PCa Cell Viability.
All cells were maintained in regular medium for 24 hours, then treated with 1 μM of the CIL-102
derivatives in SR conditions for 72 hours. MTT solution was added to the cells for 4 hours.
Absorbance was measured at 540 nm. A) LNCaP C-81 cells were plated at 1.5 x 104 cells per well
in 96-well plates and treated with an array of the CIL-102 derivatives. B) RWPE-1, LNCaP C-81,
and VCaP-AI cells were plated at 3 x 104, 1.5 x 104, and 7 x 104 cells per well, respectively, in 96well plates and treated with selected CIL-102 derivatives. Significance shown in B is comparing
the RWPE-1 cells to VCaP-AI cells. Results presented are mean ± SE. n=4x3. *p<0.05; **p<0.005;
***p<0.0005.
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Figure 4.3. Effects of CIL-102 Derivatives on PCa Cell Proliferation.
All cells were plated in regular medium for 72 hours, then conditioned to SR medium for 48 hours.
Cells were treated with CIL-102 derivatives for 72 hours and then harvested via trypsin. Cell
number was measured using trypan blue exclusion dye. A) and B) LNCaP C-81 cells were plated
at 1.5 x 104 cells per well in 6-well plates. A) Cells were treated with 0 nM, 50 nM, 100 nM, 250
nM, and 500 nM of compound 1 or 6. B) Cells were treated with 0 nM, 100 nM, 250 nM, 500 nM,
750 nM, and 1000 nM compound of 22 or 23. C) LNCaP C-81 cells from (B) were lysed and total
cell lysate was analyzed for Cyclin B1. β-actin was used as a loading control. Images were cropped
from original blots. LNCaP C-81 (D), VCaP (E), NE 1.3/NE 1.8 (F), PC-3 (G) and RWPE-1 (H)
cells were plated at 2 x 104, 1.5 x 105, 1.5 x 105, 1.5 x 104 and 1.5 x 105 cells per well, respectively,
in 6-well plates. Cells were treated with 1 μM of the CIL-102 derivative. Results presented are
mean ± SE. n=3x3. *p<0.05, **p<0.005, ***p<0.0005.
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Figure 4.4. Effects of CIL-102 Derivatives on Tumorigenicity of LNCaP C-81 Cells.
A) Boyden Chamber Transwell Assay. LNCaP C-81 cells were plated in transwell inserts at 5 x
104 cells per insert in regular medium. Medium in both upper and lower chambers contained 1 μM
of 1, 22, or 23. After 24 hours, cells in the lower chamber were stained, while cells remaining in
the upper chamber were removed via cotton swab. Images shown are at 40x magnification. Results
presented are mean ± SE. n=2x3. *p<0.05, **p<0.005, ***p<0.0005.
B) Clonogenic Assay. LNCaP C-81 cells were plated in 6-well plates at 3000 cells per well in
regular medium for 72 hours. Cells were then treated with 1 μM of 1, 22, or 23 for 6 days, with
fresh medium containing the specified treatment on day 3. On day 6, cells were stained, and the
number of colonies was counted. Plating efficiency was calculated and reported. Representative
images are at 40x magnification. Results presented are mean ± SE. n=3x3. *p<0.05, **p<0.005,
***p<0.0005.
C) Soft Agar Assay. LNCaP C-81 cells were plated at a density of 3 x 104 cells/35mm dish in
0.25% soft agarose with a base layer of 0.3% agarose. After 24 hours, cells in doublets or greater
were marked and excluded from the study. Culture medium containing 1 µM of 1, 22, or 23 was
added every 72 hours, and after 4 weeks, colonies were stained and fixed. Representative images
of colonies were taken, and the number of colonies counted. Plating efficiency was calculated and
reported. Results presented are mean ± SE; n=4x1. *p<0.05, **p<0.005, ***p<0.0005.
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Figure 4.5. Effects of CIL-102 Derivative Treatment on LNCaP C-81 Cell Cycle Progression
and Tubulin Polymerization.
A) Cell cycle analysis of CIL-102 derivative-treated LNCaP C-81 cells. Cells were plated in T75
flasks at 1.5 x 104 cells per flask in regular medium for 72 hours, then adjusted to SR conditions
for 48 hours. Cells were treated with 1 µM of 1, 22, or 23 for 72 hours under SR conditions.
Attached cells were harvested via trypsinization, fixed in 70% ethanol for 30 minutes, then washed
twice with PBS. Cells were stained with Telford reagent for 2 hours, and then cell cycle was
analyzed via flow cytometry. The data shown is a representative of three sets of independent
experiments, and similar results were obtained. n=3.
B) Confocal microscopy of LNCaP C-81 cells treated with CIL-102 derivatives. Cells were plated
on coverslips at 5 x 104 cells per 12-well plate in regular medium for 24 hours, then treated with
either control, 0.25µM, or 0.50 µM of 1, 22, or 23 for 24 hours. Cells were fixed, permeabilized,
and incubated with anti-α tubulin antibody before visualization under a confocal microscope. Color
adjustment was applied equally in all images shown. The data shown is a representative of two sets
of independent experiments, and similar results were obtained. n=2. Insets are used to visualize the
tubulin depletion with a represented scale bar of 10 µm.
C) Computational modeling of CIL-102 and derivatives binding to the α-/β-tubulin dimer (1TUB).
Images show protein surface (red and white), 2° structure (green and orange), as well as the zoomed
in image of the molecules binding to the dimer. The α-tubulin subunit is orange, while the β-tubulin
subunit is green.
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Figure 4.6. Effects of CIL-102 Derivatives on LNCaP C-81 and RWPE-1 Cell Signaling
Profile. Immunoblot analysis of CIL-102 derivatives-treated LNCaP C-81 (A) and RWPE-1 (B)
cells. LNCaP C-81 cells were plated in T75 flasks at 1.5 x 104 cells per flask in regular medium for
72 hours and then adjusted to SR conditions for 48 hours. Similarly, RWPE-1 cells were plated at
3 x 105 cells per flask then conditioned to SR medium. Cells were treated with 1 µM of 1, 22, or
23 for 72 hours under SR conditions. Control cells were treated with solvent DMSO alone. Cells
were harvested via scrapping and lysed. Total cell lysates were analyzed for AR, secreted PSA,
cPSA, Nrf2, HO-1, BAX, BclXL, p53, Survivin, and total and cleaved Caspase 3 and PARP protein
levels. Lysates were also analyzed for total and phosphorylated ERK and AKT. β-actin protein
level was used as a loading control. The data shown is a representative of three sets of independent
experiments, and similar results were obtained. Images were cropped from original blots. n=3.
*p<0.05.
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Figure 4.7. Effects of CIL-102 Derivatives on ROS Production.
(A) LNCaP C-81 cells were plated at 5x 104 cells per well in 12-well plates for 24 hours. Cells were
then treated with 1 μM of the CIL-102 derivatives for 24 hours. Mitochondrial superoxide levels
were labeled with MitoSOX fluorescence indicator for 10 minutes before the reaction was
quenched. DAPI was utilized to stain the nucleus. Fluorescence was visualized via confocal
microscopy. Color adjustment was applied equally in all images shown. The data shown is a
representative of three sets of independent experiments, and similar results were obtained. n=3.
*p<0.05, **p<0.005.
(B) LNCaP C-81 cells were plated at 1.5 x 105 cells per T75 flask for 72 hours. Cells were
conditioned to SR medium for 48 hours before being treated with the CIL-102 derivatives for 72
hours. Cells were stained with 20 μM DCF-DA for 30 minutes in the dark and subjected to flow
cytometry analysis. The data shown is a representative of three sets of independent experiments,
and similar results were obtained. n=3. *p<0.05, **p<0.005, ***p<0.0005.
(C) RWPE-1 cells were plated at 1x 105 cells per well in 12-well plates for 24 hours. Cells were
then treated with 1 μM of the CIL-102 derivatives for 24 hours. Mitochondrial superoxide levels
were labeled with MitoSOX fluorescence indicator for 10 minutes before the reaction was
quenched. DAPI was utilized to stain the nucleus. Fluorescence was visualized via confocal
microscopy. Color adjustment was applied equally in all images shown. The data shown is a
representative of three sets of independent experiments, and similar results were obtained. n=3.
*p<0.05, **p<0.005.
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Figure 4.8. Effects of CIL-102 Derivatives on Docetaxel-Resistant PCa Cell Proliferation.
A) Docetaxel-sensitive and docetaxel-resistant PC-3 cells were plated at 1 x 104 cells per well in
regular medium for 72 hours, then conditioned to SR medium for 48 hours. Cells were treated
with 10 nM docetaxel or 1 µM of the CIL-102 derivatives for 72 hours and then harvested via
trypsin. Cell number was determined with trypan blue exclusion dye assay. Results presented are
mean ± SE. n=3x3. *p<0.05; N.S., non-significant.
B) Docetaxel-sensitive and docetaxel-resistant LNCaP C-81 cells were plated at 2 x 104 cells per
well in regular medium for 72 hours, then conditioned to SR medium for 48 hours. Cells were
treated with 3 nM docetaxel or 1 µM of the CIL-102 derivatives for 72 hours and then harvested
via trypsin. Cell number was determined with trypan blue exclusion dye assay. Results presented
are mean ± SE. n=3x3. *p<0.05; N.S., non-significant.
C) Docetaxel-sensitive and docetaxel-resistant VCaP-AI cells were plated at 1 x 105 cells per well
in regular medium for 72 hours, then conditioned to SR medium for 48 hours. Cells were treated
with 2 nM docetaxel or 1 µM of the CIL-102 derivatives for 72 hours and then harvested via trypsin.
Cell number was determined with trypan blue exclusion dye assay. Results presented are mean ±
SE. n=3x3. *p<0.05; N.S., non-significant.
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Figure 4.9. Proposed Mechanism of CIL-102 Derivatives. Our data have demonstrated that
CIL-102 derivative treatment results in increased mitochondrial ROS generation as well as
destabilization of microtubules, resulting in cell cycle arrest. Interestingly, increased ROS
production upon treatment with the CIL-102 derivatives led to activation of p53 and induction of
cleavage of Caspase 3 and PARP signaling, indicating that the cell is undergoing cell death.
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Chapter 5

Conclusions
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6.1 Summary
The overall goal of my work is to advance therapeutic strategies for treatment of CR PCa,
a currently incurable, lethal disease. Importantly, due to our laboratory’s access to multiple
progressive PCa cell line models, we have a unique opportunity to investigate aspects of the disease
in a clinically relevant system. Importantly, my work all revolves around a central theme of ROS
and how this can promote PCa progression to an aggressive AI phenotype and understanding how
we can utilize these molecules to treat a currently fatal disease.
In my first body of work, I examine the effects of increased ROS levels, specifically that
mediated by p66Shc, on AS PCa growth and migration. ROS has been shown to promote
proliferation and migration in various types of cancer, thus we theorized p66Shc and/or ROS also
promotes an aggressive phenotype in CR PCa. Initially, we analyzed three PCa cell lines, with both
AS and AI counterparts, to demonstrate that the AI PCa cells were able to proliferate at more rapid
rates in both regular and SR conditions. The AI PCa cells also had greater colony formation and
migratory potential compared to their AS counterparts. Further, AI cells had higher basal levels of
ROS as well as enhanced activation of proliferative, migratory, and survival signaling pathways.
Interestingly, AI PCa cells have increased levels of pro-oxidant p66Shc, suggesting that this
molecule was important for the AI phenotype. Increased androgen biosynthesis and activation of
AR, as denoted by PSA levels, promote the AI phenotype within PCa cells [131-134,137] (Fig.
3.3D), which correlates with data that demonstrates that p66Shc protein is stabilized by androgens
and AR activity [152, 191]. This suggests that elevation of p66Shc protein levels is a direct effect
of the progression to AI PCa. Because pro-oxidant p66Shc is elevated in AI PCa cells, we further
hypothesized that ROS treatment alone could promote AS PCa proliferation and migration, so we
treated LNCaP-AS, MDA-AS, and VCaP-AS cells with H2O2 and/or NAC and determined that
H2O2 treatment enhanced proliferation and migration, while NAC treatment reduced these
tumorigenic characteristics. Further, NAC treatment was able to mitigate H2O2-mediated growth
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and migration. We also demonstrated that mitochondrial superoxide and cellular H2O2 levels were
increased in LNCaP-AI cells and p66Shc subclones compared to LNCaP-AS and V1 cells,
suggesting that p66Shc may be a source of increased ROS in AI PCa cells. A phosphoprotein
microarray demonstrated that in LNCaP-AI cells and p66Shc subclones, several proliferative and
migratory pathways were activated compared to LNCaP-AS and V1 cells. Interestingly, these same
pathways were activated upon treatment of LNCaP-AS cells with H2O2, and reduced upon
knockdown of p66Shc in p66Shc subclones, confirming the ROS-sensitivity of PAcP, ErbB-2,
AKT, mTOR, ERK, FOXM1, PYK2, and Rac1. Although AR can activate these pathways, our
data suggests that it is p66Shc and subsequent ROS production that is the primary influence of
enhanced ErbB-2, AKT, mTOR, ERK, FOXM1, PYK2, and Rac1 activity due to oxidation of PAcP
[136,141]. Lastly, orthotopic injection of PCa cells into mouse prostates revealed that LNCaP-AI
and p66Shc subclones, but not LNCaP-AS and V1 cells, were able to metastasize in xenograft
models. Together, this data supports the hypothesis that AS PCa tumorigenicity can be enhanced
by ROS, such as that generated by pro-oxidant p66Shc. This study warrants the development of
p66Shc-targeted therapies for utilization in CR PCa.
In my second body of work, I investigate a panel of novel CIL-102 derivatives as potential
therapeutic agents for CR PCa as well as docetaxel-resistant PCa and investigate their mechanism
of inhibition. This third generation of compounds was synthesized because of their known activity
to inhibit tubulin polymerization as well as their enhanced selectivity compared to other
microtubule-targeting compounds, such as docetaxel. Second generation compound 1 was altered
through the addition of various substituent groups in hopes of synthesizing a compound that had
increased selectivity to reduce adverse side effects in patients. Initial screening of the compounds’
ability to suppress LNCaP-AI cell growth revealed compounds 22 and 23 have a similar inhibitory
activity to that of compound 1 but were also less toxic to noncancerous epithelial RWPE-1 cells.
Not only were the third generation compounds 22 and 23 more selective than compound 1, all three
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compounds were effective against both adenocarcinoma and NE-like PCa cells and effectively
reduced PCa tumorigenicity, including migration and colony formation. The inhibition of tubulin
polymerization was demonstrated to result in the induction of cell death in PCa cells due to
increased ROS production that led to p53 activation and cleavage of Caspase 3 and PARP.
Additionally, cell cycle analysis shows that 1, 22, and 23 arrest the cell cycle in G2 phase as well
as strongly induces apoptosis. Further, all three compounds showed similar efficacy in growth
inhibition of docetaxel-sensitive and docetaxel-resistant PCa cells. Thus, third generation CIL-102
derivatives 22 and 23 show promise as future therapeutic agents for the treatment of CR PCa and
docetaxel-resistant PCa due to its selective growth inhibition, increased ROS production, and
activation of pro-apoptotic pathways.
Bringing these three pieces of work together, it demonstrates that ROS does in fact play a
vital role in the progression of PCa and as such manipulating ROS levels can be utilized as a
therapeutic approach. The importance of these studies has an interesting feature: it moves treatment
of CR PCa away from targeting AR and reducing cellular androgen levels, which can often result
in resistance and progression to the CR phenotype. Even at the CR PCa stage, AR is commonly a
target because CR PCa cells continue to find mechanisms to exhibit functional AR or bypass this
signaling pathway so that they may continue to survive and proliferate [11-18]. CR PCa treatments
need to look beyond AR and its primary signaling pathway to find other functional molecules that
will not shortly be overtaken by resistance as has been seen with ADT, enzalutamide, casodex, and
abiraterone acetate [19,20]. In our studies, we demonstrate that p66Shc elevation is vital to
progression to the AI PCa phenotype. Although my study on CIL-102 derivatives does not directly
look at utilization of p66Shc as a target, it does show that elevation of ROS levels has great potential
as a modality for promoting cancer cell death in a selective manner.
Our studies are not fully complete and continue to leave unanswered questions relating to
how ROS functions in clinical PCa as well as the mechanism of action of our ROS-producing CIL-
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102 derivatives. The next step to complete these studies is focused on immunohistochemistry
analysis of p66Shc protein in clinical PCa tissue samples. We did not complete these studies due
to both the rarity of clinical CR PCa samples and ensuring that we had effective anti-p66Shc
antibodies to determine the protein levels of these molecules in tissue. Currently, very few samples
if any, currently exist that are able to match AS and CR PCa tissue samples from the same tumor.
These samples would be extremely helpful for corroborating our in vitro studies on p66Shc
elevation upon disease progression. We currently have obtained hormone-sensitive and hormonerefractory PCa tissue samples as well as PCa metastasis tissue samples from the Prostate Cancer
Biorepository Network for analysis of protein levels of p66Shc. However, these PCa tissues may
only highlight a subpopulation of tumors with p66Shc overexpression in AS and AI tumors, which
would be difficult to reconcile with our studies, especially when we cannot match AS to AI tumors.
Further understanding of the in vivo function of p66Shc protein, as well as our CIL-102
derivatives remains necessary. Orthotopic and subcutaneous injections of both LNCaP-AI and
p66Shc subclones do in fact show that p66Shc overexpression can promote metastasis and AI
proliferation. An important next step would be to demonstrate the vital role of p66Shc in disease
progression. An inducible promoter would provide this type of control over p66Shc expression to
show that low levels of p66Shc protein result in dormancy in castrate conditions, while inducing
expression of p66Shc via doxycycline treatment after several days or weeks should result in a rapid
rate of tumor growth and demonstrate the transition from AS to AI. Another important area within
our studies that we did not complete was determining the efficacy and selectively of CIL-102
derivatives to suppress tumor growth in vivo. If these results mirrored what we have seen in the in
vitro work in which the molecules effectively suppressed PCa growth while having relatively little
toxicity to normal noncancerous cells, it would have strengthened our findings and helped to push
these molecules into human clinical trials.
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Another question that arises from our studies relates to implementation of these studies via
treating patients through the manipulation of ROS. This can become a very tricky double-edged
sword because targeting ROS can be non-selective. Radiation is known to cause a multitude of both
short- and long-term negative side effects due to ionizing radiation affecting both normal and
cancerous cells alike. Normal noncancerous cells often have narrower thresholds for ROS
compared to cancerous cells and as such increased ROS in those particular cells could result in
mutations that promote further cancer initiation. Some normal noncancerous cell types affected by
the radiation or other ROS-producing treatments could be pushed to excessive ROS levels leading
to cell death leading to treatment-related diseases such as fibrosis, low blood count, or skin damage.
In the case of PCa, increasing ROS levels may promote the development of more aggressive PCa
AI cells from residual AS PCa cells as we see can occur when we treat AS PCa cells with H2O2
(Fig. 3.4). All of these outcomes could very well make the situation dramatically worse for patients
and is something we want to avoid completely.
Moving forward, we hope that our target p66Shc is only highly expressed in the cancerous
tissues and then provide a selective means of manipulation of ROS that would not create more
problems than they would solve. Several studies have demonstrated the ubiquitous expression of
p52Shc and p46Shc under the regulation of one promoter within a multitude of cell types [192],
while p66Shc expression remains more selectively expressed through an alternate promoter [193].
Interestingly, p66Shc is often absent in blood lymphocytes, hemapoietic cells, and neurons until
these cells are undergo apoptosis [194,195]. Similarly, there is often little to no expression of
p66Shc in many types of normal tissues, but cancerous forms of these cells have elevated levels of
this particular pro-oxidant [191,197-199]. Taking these studies into consideration along with with
our data in which little to no detectable p66Shc protein in normal prostate epithelial RWPE-1 cells
suggests that targeting p66Shc could be a great selective therapeutic strategy. Similarly, the
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selectivity of CIL-102 derivatives gives hope that treatment with these molecules would not result
in increased ROS levels in our normal cells and therefore provide few side effects to patients.
An important discrepancy to discuss that we often find in the literature is that numerous
studies in a variety of diseases suggest that p66Shc mitochondrial location is associated with
apoptosis. They discuss how the mitochondrial location of p66Shc is utilized as a sensor for
oxidative stress and then triggers apoptosis [30,200,201]. The apoptosis brought about by
mitochondrial

translocation

then

promotes

development

of

health

issues

including

ischemia/reperfusion [202,203], nephropathy [204], liver fibrosis [205], etc. As such, numerous
reports demonstrate the advantages of the deletion of p66Shc to promote organism lifespan [206].
In contrast to our studies, several groups have mentioned that p66Shc mitochondrial translocation
can result in apoptosis in cancers [207-209]. Furthermore, several studies have shown that p66Shc
reduces EMT, cell migration, and invastion in lung cancer [210,211] and oral squamous cancer
[212].
This raises many questions as to why increased mitochondrial translocation in our systems
correlate with an aggressive disease phenotype instead of increased apoptosis. It has been well
documented that the same protein can be involved in dual tumor promotion and suppression even
within the same cancer type. The most plausible way to explain this phenomenon is to say that
different cancers can utilize the same protein in different fashions. Looking particularly at p66Shc,
we could explain the pro-apoptotic effects by potentially higher basal levels of ROS in lung cancer.
The elevation of a protein that promotes ROS generation in this cancer would then tip the scales of
ROS to an excessive level, resulting in cell death. We cannot confirm this hypothesis because ROS
levels were not measured in these papers, and no direct comparison of basal ROS levels has been
completed to compare different types of cancers. Interestingly, we see similar results in which
p66Shc promotes an aggressive phenotype with increased proliferation and migration in breast and
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ovarian cancers, both of which are regulated by hormones [26,191,213]. This could suggest that
the pro-proliferative effects of p66Shc rely on hormone signaling.
When we analyze these articles in the context of methodology, we cannot confidently say
whether these functional studies on p66Shc promoting cancer apoptosis were completely sound
relating to p66Shc overexpression via cDNA transfection. Little detail was offered within these
manuscripts of how the p66Shc plasmid was obtained or generated and at what concentration the
plasmid was transfected. These small details in plasmid concentration or which promoter is utilized
for p66Shc expression could lead to discrepancies in the results obtained leading to the conclusion
that overexpression of p66Shc can easily result in apoptosis due to increased ROS. This could
suggest that cell biology can be greatly altered upon minute alterations in the ROS balance and that
care should be taken to understand the function of these ROS producing or scavenging molecules.
One way to confirm these cell biology results is through varying concentrations of the plasmid
itself. Within our studies, we showed a dose-dependent decrease of proliferation upon increased
concentration of p66Shc shRNA transfected, and our three p66Shc subclones with varying levels
of p66Shc upon cDNA transfection show corresponding rates of enhanced proliferation
[67,131,141], therefore we are very confident in our results that p66Shc promotes PCa progression
to the AI phenotype.
In the context of ROS production meditated by p66Shc to promote an aggressive cancer
phenotype, several reports have demonstrated that p66Shc primarily utilizes Rac1 for ROS
generation via NOX enzymes [214-216]. Many other studies, including our own publications,
suggest that mitochondrial localization is the key to increased proliferation and migration in cancer
[66,217,218]. Although we do not disagree that p66Shc can and does promote ROS generation via
NOXs, our data strongly support that p66Shc mitochondrial localization is the primary source of
p66Shc-mediated ROS production in our system to promote PCa proliferation and migration. These
data indicate that mitochondrial superoxide production (Fig. 3.5) and mitochondrial localization of
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p66Shc (Fig. 4.5) are greatly reduced upon transfection of LNCaP-AI cells or p66Shc subclones
with p66Shc shRNA. Cytoplasmic p66Shc protein remains after p66Shc knockdown, but we still
see a strong reduction in proliferation and migration. Further, transfection with W134F redoxinactive mutant that can no longer bind to Cytochrome C results in a similar phenotype (Fig. 4.3)
[141], which again supports the hypothesis that mitochondrial superoxide has a greater role in our
model than NOX activation via Rac1.
In summary, the studies within this thesis describe a novel ROS-based mechanism for PCa
disease progression that have several different potential applications in the treatment of clinical
PCa. The most obvious implication is the finding of a novel biomarker for aggressive PCa. Elevated
p66Shc correlates with androgen-independence in vivo and in vitro, and therefore analyzing patient
PCa tissues for p66Shc protein before treatment could help direct physicians towards different
therapeutic options. For example, treatment of p66Shc subclones with current FDA-approved
chemotherapeutic for CR PCa such as docetaxel, abiraterone acetate, enzalutamide, and casodex is
less effective than treatment with AS V1 control cells by almost 20% (data not shown). Therefore,
in cases in which p66Shc in elevated, physicians should look to alternative therapies, potentially
those that lead to increased ROS generation like cisplatin, to effectively treat this patient
population. Unfortunately, cisplatin is not currently approved for treatment of CR PCa, however
there are currently clinical trials ongoing to determine the response to and toxicity of cisplatin in
CR PCa patients that no longer respond to enzalutamide (NCT03275857). These clinical trials are
currently recruiting and are set to be completed by January 2020. Our data among others strongly
warrant these studies to promote the utilization of these molecules in clinical cancer treatment.
There is also room for new small molecule inhibitors, particularly development of anti-p66Shc
small molecules or antibodies that could block p66Shc-mediated ROS production. These
compounds would be highly beneficial for not only the treatment of CR PCa, but have potential for
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utilization in other cancers in which p66Shc is highly expressed and promotes an aggressive tumor
phenotype such as breast and ovarian cancers.

6.2 Future Directions
While the results of these studies are promising for the future treatment of CR PCa, further
studies are required, particularly in order to move these findings towards application in a clinical
setting. The studies highlighted within this thesis all point towards the manipulation of ROS as vital
towards PCa progression and a beneficial means of treating this disease, but more work is necessary
to provide further insight into mechanisms of action and selectivity before human trials begin.
While the investigation of novel therapeutic compounds is vital for the future of PCa
research, it is also necessary to continue examining the underlying mechanisms of PCa progression
towards castration-resistance and aggressive metastatic phenotype. My second and third bodies of
work demonstrate the elevation of p66Shc protein level as a driving force behind PCa progression
and the development of AI and identify a number of critical proteins in the mechanism. While the
mechanism in which p66Shc activates ErbB-2 and its downstream signaling cascade clearly
revolves around oxidation and inactivation of cPAcP [136], it is not immediately known how other
ROS-sensitive molecules, such as ABL1, ACK1, AMPKα2, ANKRD3, APP, and MET function in
the context of PCa. Further investigation of their interaction will be the subject of future studies
utilizing our PCa progressive model.
Presently, the next step in this investigation is to carry out in vivo experiments to investigate
the potential of p66Shc as a therapeutic target, of which there is currently no inhibitor compound
available for p66Shc. Moreover, inhibition of p66Shc may not be appropriate for all stages of PCa
due to its promotion of ROS generation. Early stages of PCa typically have lower levels of ROS
and may benefit from p66Shc-mediated ROS production; thus p66Shc may be a good target for
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these cells. However, late-stage PCa may have much higher basal levels of ROS, which induces
cellular stress and in some cases apoptosis. Inhibition of p66Shc in these cells may actually aid
their survival. Furthermore, PCa is notorious for having a heterogeneous makeup that can include
both AS and AI cells, making a therapy which targets the source of ROS all the more complex.
Therefore, it is reasonable to assume aggressive metastatic PCa cells, which possess elevated
p66Shc levels, must also have elevated antioxidant molecules to regulate ROS production and keep
it at optimal concentrations. Targeting antioxidant molecules in metastatic CR PCa has the potential
to be an effective therapeutic strategy by impeding their ability to regulate ROS produced by
elevated p66Shc levels. In addition, combined inhibition of p66Shc as well as some of its
downstream signaling partners such as Rac1, ErbB-2, ERK, AKT, mTOR, and PYK2, may also be
an effective means of treatment. Another interesting thought to pursue would be to look at the
immunology response within the tumor upon treatment with pro-oxidants. Extremely high ROS
levels could promote necrosis, and thus the messy cell death could alert immune cells to the
cancerous area and provide additional anti-tumor effects. This would be an exciting and unique
finding as current treatments for CR PCa like casodex, enzalutamide, and abiraterone acetate- all
of which target androgen biosynthesis- often result in cell cycle arrest until the tumor can find
alternative pathways to promote cell survival.
The mechanism governing p66Shc promotion of an aggressive tumor phenotype remains
unclear and will continue to be a topic of interest. The pursuit of the effects of p66Shc cDNA
transfection in noncancerous prostate epithelial cell line RWPE-1 is currently ongoing. Preliminary
results demonstrate that p66Shc transfection of RWPE-1 prostate cells results in increased 2D and
3D colony formation, suggesting its role as an oncogenic protein. Further studies will continue to
understand the mechanism by which p66Shc promotes this tumorigenic phenotype in normal
prostate epithelial cells via proteomics analysis and immunoblotting.
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Future work on the CIL-102 derivatives is warranted in multiple areas. First, the
mechanism of action of CIL-102 derivatives on PCa inhibition requires further clarification. While
compounds 22 and 23 clearly reduce PCa adenocarcinoma and NE-like PCa, the mechanism by
which this occurs is still unclear. Although we see anti-cancer effects with all three CIL-102
derivatives, differences in tubulin polymerization and cell signaling suggest an alternate
mechanism of action for third generation compounds 22 and 23 compared to second generation
compound 1. Whether this relates to the direct targets of these molecules or the binding affinity is
remains unknown. Another possibility is that there are different binding targets in which one
generation of compounds binds to tubulin while the other binds to DNA as quinolones often do.
We could analyze the binding of the CIL-102 derivatives to either tubulin or DNA utilizing a
spectrophotometer [174] or UV-Vis spectroscopy [220]. Further, the mechanism by which
inhibition of tubulin polymerization that results in ROS generation is unknown and needs additional
clarification. One potential source of the ROS induction could be due to DNA damage or
mitochondrial dysfunction, which has been demonstrated in a variety of quinolone compounds
[221]. Thus understanding the effects of the CIL-102 derivatives on DNA oxidation and nucleotide
base repair as well as mitochondrial activity would be an excellent avenue to explore with these
compounds to continue our knowledge of how these molecules function. In addition, we can
determine if the CIL-102 derivatives function is through oxidization of microtubules to promote
depolymerization, as seen in several other studies [188,189]. This ‘chicken or egg’ conundrum
could be examined through immunoprecipitation of microtubule subunits or microtubuleassociated proteins after CIL-102 treatment and a subsequent immunoblotting for protein oxidation
could be performed as well to confirm microtubule oxidation. In addition, mutation of easily
oxidize residues, such as those with thiols, within the tubulin monomers could be performed, as
long as these mutations do not lead to depolymerization themselves, which would allow for
determination of an effect on microtubule structure upon treatment with the CIL-102 derivatives.
Binding of CIL-102 derivatives to tubulin could also be determined via treatment of cells with
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radiolabeled forms of these molecules followed by immunoprecipitation of tubulin subunits.
Furthermore, in vivo studies of pharmacokinetics and tumor growth and metastasis inhibition are
also necessary to ensure that these compounds are not only effective in vitro and could be utilized
to treat clinical CR PCa. Future work on these compounds should investigate the effects of CIL102 derivatives on other types of cancers that are commonly treated with taxanes, such as breast
and ovarian cancers as well as their docetaxel-resistant forms, thus expanding the pool of patients
which can benefit from these therapeutic agents. Future investigation of their mechanism of
inhibition and improvement on their structure will enhance the clinical application of the CIL-102
derivatives.
Regarding the mechanism of action of selectivity of our CIL-102 derivatives there is still
much that could be explored and expanded upon to further the development of selective anti-cancer
molecules. While we do see selectivity between both prostate adenocarcinoma and prostate
neuroendocrine cancer cells compared to normal prostate epithelial RWPE-1 cells, we cannot fully
explain this phenomenon. The increased protein levels of BclXL upon treatment with compounds
22 and 23 demonstrate that there is less cell death occurring compared to second generation
compound 1 and the mechanism of the upregulation of this protein is of interest. The other strange
characteristic we see is a reduction in mitochondrial superoxide levels upon treatment with the CIL102 derivatives compared to control cells. Could this be a defense mechanism through increased
expression of superoxide dismutases or a side effect of the anti-apoptosis response? The exploration
of these ideas would be of great value to help understand a successful anti-apoptotic response in
noncancerous cells and then provide insight on how to design and synthesize more selective anticancer drugs.
Moving our studies into the realm of the bigger picture of ROS treatment for CR PCa, or
other cancers, provides numerous possibilities. The balance of ROS can also be manipulated via
antioxidants, although these clinical trials have not seen much success when it comes to reduction
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of risk of cancer development or disease progression. Several clinical trials, including the infamous
ATBC and SELECT trials, have utilized ROS scavenging molecules α-tocopherol, β-carotene,
selenium, and vitamin E to attempt to lower ROS levels in the prevention of cancer, but some trials
found that these antioxidants led to an increased cancer risk [118-122]. Our data in which treatment
of AI PCa cells with NAC stimulated cell growth could explain how reduced ROS may have led to
a more aggressive tumor (Fig. 4.1). Furthermore, other studies have shown similar results in which
treatment with antioxidants promotes a more aggressive phenotype most likely due to higher basal
levels of ROS than would be ideal for optimal tumorigenicity [222,223]. This would suggest that
antioxidants should not be utilized as anti-cancer treatments and no further studies, especially in
human clinical trials, should be undertaken. These data only provide more strength to promoting
increased ROS levels for cancer therapies instead of utilizing antioxidants to reduce ROS. These
antioxidant molecules may be better suited for cancer prevention if studies were applied towards a
younger population and were continuously monitored throughout their life instead of providing
these supplements to an older population that may have small undetectable populations of
cancerous cells that could expand under the right oxidative conditions.
Within clinical practice, we currently utilize radiation to induce ROS generation and
promote DNA damage, however, this particular therapy can be toxic due to its inability to
distinguish cancerous cells from noncancerous cells. A high importance should be focused on
finding successful radioprotectants that can prevent or minimize damage to noncancerous cells.
Another avenue could focus on other types of small molecules that could selectively target the
cancerous cells and leave them more susceptible to lower doses of radiation that would be less toxic
to normal tissues. Current clinical trials emphasize the combinations of radiation and ADT
(NCT01368588), Apalutamide (NCT03371719), or docetaxel (NCT03070886); however, clinical
trials could easily expand to include non-traditional therapeutics for CR PCa, such as cisplatin. The
studies may have to be stringent with eligibility criteria such as only the inclusion of a patient
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population with high p66Shc or NOX protein levels. Additionally, with constant synthesis of novel
molecules in chemistry labs and biopharmaceutical companies, there always remains the possibility
for emerging new small molecules that promote ROS generation and would be effective therapeutic
options for CR PCa as well as other types of cancers.
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